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ABSTRACT 
 
 Older adults account for almost one-third of all medications prescribed in the US. 
Of special concerns are the high rates of medication non-adherence in this population. 
Understanding the drivers of the medication non-adherence among the older population 
can inform effective public health interventions. This dissertation is divided into three 
separate sections, and each section examines different determinants of the medication 
non-adherence.  
The first section used systematic literature review and meta-analysis to describe 
the prevalence of medication non-adherence and overview the association between 
patient-provider relationship and medication non-adherence among community-dwelling 
older adults. Ten studies were included in this review. The mean prevalence rate of 
medication non-adherence was 33%. Information exchange was positively associated 
with medication non-adherence, but discussion about barriers was negatively associated 
with medication non-adherence. 
The second section used multiple linear mixed-effects models to examine the 
long-term impacts of the Chronic Disease Self-Management Program (CDSMP) on 
medication non-adherence in older adults. Medication adherence did not improve 
significantly at the 6-month follow-up assessment (p=0.518) but improved significantly 
at the 12-month follow-up assessment (p=0.021). Among those with major depression at 
the baseline assessment, the short-term improvements in depression (p=0.002) and self-
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rated health (p=0.045) were associated with improved medication adherence at the 12-
month follow-up assessment.  
The third section used structural equation modeling to examine the causal paths 
between poverty, patient attitudes, and cost-related medication non-adherence (CRN). 
Six percent of the participants reported CRN in the past 12-months. The final model 
showed a good-to-fair fit. As hypothesized, the effects of poverty on CRN was mediated 
through the medication affordability, access to healthcare, and overall patient 
satisfaction.  
Medication non-adherence is a complex problem that is rooted in multitudes of 
inter-related factors, and the three sections have examined multiple modifiable factors, 
suggesting several points of intervention for improving medication adherence among 
older adults.  We call for more senior-friendly public health interventions that address 
the modifiable barriers (e.g., patient-provider relationship, depression, self-rated health, 
and patient attitudes). Future studies are needed to understand the underlying complexity 
and guide the future interventions. 
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1. INTRODUCTION 
  
 
1.1. Background 
Over the past decades, increased use of pharmacotherapy or medication treatment 
was observed in the US [1]. About 90% of older Americans are on at least one 
prescription medication, and more than one-third of older adults are on polypharmacy 
(i.e., five or more prescription medication) [2]. The cost of prescription medication 
reached $265 billion in 2013 [3], and the cost of prescription medication is expected to 
rise even further in the next decades with the growing size of an older adult population 
[4]. 
Assuming evidence-based prescription is practiced by prescribers, prescription 
medication can only be as effective as it is administered as prescribed. Poor medication 
adherence is associated with treatment ineffectiveness, adverse health outcomes, 
increased healthcare costs, and even death [5, 6]. For instance, poor adherence to 
adjuvant hormonal medication (e.g., tamoxifen) was associated with shorter recurrence 
periods, loss of life years, increased medical costs, and worse quality of life in female 
breast cancer patients [7]. Recent studies support the notion that improved medication 
adherence significantly lowers healthcare costs [8, 9]. 
Given the context, poor medication adherence has been a persistent public health 
challenge. Based on the quantitative review of 328 studies, DiMatteo reported that one-
in-five patients did not adhere to his or her prescription medication [10]. With the 
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expectation that the rates of medication non-adherence would be underestimated in 
clinical trials due to the attention received by the patients, Osterberg and Blaschke [11] 
reported medication adherence rates of 43 to 78% (or medication non-adherence rates of 
22 to 57%). Based on a more recent review [12], the rate of medication non-adherence 
has remained problematic (43%). 
Past research in the area has expanded our understanding of factors influencing 
medication adherence (e.g., patient-provider relationship) and identified potential 
leveraging points for improving medication adherence. However, what we know and 
how we intervene in this persistent public health issue can be further improved via 
additional research. For example, while patient-provider relationship has been suggested 
as an influencer of medication adherence, there is a limited understanding about how 
different components of the relationship or types of medical interaction influence 
medication adherence. Therefore, this dissertation aims at investigating the modifiable 
factors that may drive medication adherence and thereby inform interventions for 
promoting medication adherence in older adults. The core components of this 
dissertation are three separate researches that involve investigation of the association 
between medication adherence and different modifiable factors.  
Before delving deeper into the dissertation research, this section provides the 
background by providing a brief overview of how medication adherence is defined and 
measured, as well as its theoretical underpinning.  
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1.2. Definition of Medication Adherence 
The World Health Organization (WHO) [13] defines adherence as “the extent to 
which a person’s behavior – taking medication, following a diet, and/or executing 
lifestyle changes, corresponds with agreed recommendations from a healthcare provider” 
(p.17). The International Society for Pharmacoeconomics and Outcome Research 
(ISPOR) [14] provides a more detailed definition: “the extent to which a patient acts in 
accordance with the prescribed interval and dose of and dosing regimen.” The two 
definitions share the common idea that medication adherence refers to the degree to 
which a patient’s behavior conforms with the prescription instruction. The ISPOR’s 
definition provides a more specific criteria of medication adherence, but the definition 
may imply a passive role of a patient in a healthcare setting. On the other hand, the 
WHO’s definition, by using the term ‘agreed recommendation,’ highlights the active role 
of patients in their healthcare. 
In the past literature, adherence has also been used synonymously with 
compliance and persistence. For example, Vrijens et al. [15] included initiation, 
implementation, and discontinuation as components of adherence behavior. However, 
the ISPOR distinguishes persistence from adherence, such that persistence is defined as 
the duration of time since the treatment initiation to the discontinuation. The lack of 
standardized definitions results in inconsistencies and difficulties in summing or 
comparing outcomes from different studies [16]. In research practices, the difficulties in 
differentiating the terms is partly associated with the difficulties in operationally 
distinguishing those terms. 
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1.3. Operational Definition of Medication Adherence 
Operationally, medication adherence can be defined in a variety of ways. Direct 
observation by caregivers or healthcare providers is one of many ways to measure 
medication adherence. Direct observation allows collecting multiple aspects of 
medication adherence (e.g., timing, dosages, and frequencies), but the direct approach is 
not always feasible for outpatients and can be costly. Potential bias with the 
measurement can be induced from patients’ desire to be viewed favorably by the 
researchers, caregivers, and healthcare providers [17-20]. 
Alternatively, patients can be asked to self-report medication adherence 
behaviors via interview or standardized questionnaires (e.g., Morisky medication 
adherence scale (MMAS) [21]). Sometimes, physicians can be asked about how well 
their patients conform with the prescription. More objective measures include pill 
counts, secondary data approach, biochemical assessment, and electronic monitoring. 
Pill counts refers to counting remaining number of pills. Medication Possession Ratio 
(MPR) is one of the most commonly-reported secondary data approach. Using the 
existing electronic health records, MPR estimates the proportion of total days covered by 
the medication over the number of days between the first and last refill. Pill counts or a 
secondary data approach may be accompanied by the billing information or insurance 
claims for more accurate information. Biochemical assessment (e.g., urine or blood 
analysis) assesses the presence of and amount of biochemical substances and cells that 
indicate intake of the medication. An example of electronic monitoring is medication 
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event monitoring system, which records the date and time a medication container was 
opened. 
Despite the presence of multiple modes of measuring medication adherence, 
there is no “gold standard.” These methods only provide proxy measures of medication 
adherence. Even the direct observation method may not be able to catch patients hiding 
medication under their tongue. Both pill counts and medication event monitoring system 
are based on the assumption that missing pills or opening containers indicate the amount 
of medications consumed or frequency of medication consumption by the patients. 
Biochemical assessment outcome could depend on the individual’s metabolism rate and 
the types of medication. Each measurement approach has benefits and drawbacks, and it 
is recommended to use multiple approaches for a more accurate measure of medication 
adherence [13, 22]. 
 
1.4. Conceptual Framework 
According to Leventhal and Cameron [23], there are five categories of theoretical 
perspectives to examine medication adherence: biomedical, behavioral (operant and 
social learning), communication, cognitive (rational decision), and self-regulatory 
theories. The biomedical perspectives view patients as passive recipients of healthcare 
and focus on dispositional characteristics (e.g., demographic and personality 
characteristics) of patients rather than contextual or cognitive factors. The behavioral 
models incorporate internal and external cues to the adherence behavior, behavioral 
patterns, and habituation. An example of the behavioral models is Bandura’s Social 
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Learning Theory [24]. The communications perspective, as its name implies, focuses on 
communication to patients about adherence and focuses on development and delivery of 
message and receipt, comprehension, and acceptance of the message. The rational belief 
models view rational thought-process (e.g., patients’ perceived benefits and barriers of 
engaging the behavior) as the key determinant of the behavior. An example of a rational 
belief model is the Health Belief Model [25]. The self-regulatory models view patients 
as active decision-makers about their adherence behavior. The self-regulatory models 
typically incorporate three stages: the cognitive representation of health threat, plan of 
action, and appraisal or coping. Unlike behavioral or rational belief models, the self-
regulatory models incorporate the potential influence of emotional reactions at all three 
stages. While all five categories of theories add value to understanding and predicting 
medication adherence, these traditional theories tend to focus on one or two dimensions 
of the known risk factors.  
A general consensus is that medication non-adherence is derived by the interplay 
of multitudes of factors, beyond just intrapersonal or interpersonal factors as described in 
many traditional models. The WHO’s multidimensional adherence model (MAM) was 
developed based on years of empirical research evidence [13]. The WHO’s MAM 
describes five categories of factors that drive treatment adherence in long-term 
conditions. The five categories are patient-related factors (e.g., age, gender, attitudes, 
and knowledge), health condition-related factors (e.g., symptom severity and 
depression), treatment-related factors (e.g., complexity, treatment duration, and 
treatment cost), healthcare system-related factors (e.g., patient-provider relationship), 
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and socioeconomic factors (e.g., education, ethnicity, social support, and financial 
status) [21]. Unlike the traditional behavioral health models, the WHO’s MAM includes 
factors that are beyond the individual-level factors, and it somewhat reflects the shift in 
the public health perspective away from victim (patient)-blaming and towards a systems 
perspective. Within the systems perspective, patients are structurally and functionally 
related to other parts of the system (e.g., healthcare providers). Wu et al. [26] used the 
MAM to determine whether the five dimensions of factors would predict medication 
adherence among patients with heart failure. The study finding supported some of the 
factors, but not all of the factors in the MAM were associated with medication adherence 
at 3- and 6-month follow-up assessments in their study population (Wu et al., 2008). 
One plausible explanation for the observation may be related to the fact that the MAM is 
not conceptualized specifically for medication adherence, but for general treatment 
adherence [26]. Also, one major weakness of the MAM is that the model does not 
explain how different categories of factors interact or influence adherence behavior. 
There have been attempts to combine traditional models (or at least constructs of 
the traditional models) with empirical evidence. Piette et al. [27] proposed a conceptual 
framework that describes the effects of patient-, medication-, healthcare providers-, and 
healthcare systems-related factors on the relationship between patients’ adherence to 
their medication and out-of-pocket cost related to their medication. Unlike the MAM, 
Piette’s model explains how different drivers influence a patient’s medication adherence 
behavior. This dissertation did not utilize Piette’s model, because the conceptual 
framework was specific to cost-related medication non-adherence.  
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Instead, this dissertation utilized a conceptual framework that was described by 
McHorney [28]. Named as the Proximal-Distal Continuum of Adherence Driver Model, 
the conceptual framework maps the drivers of medication adherence along an etiological 
continuum of impact-strengths based on empirical evidence. Based on empirical 
evidence, the prepositions for the McHorney’s adherence model were: (1) lack of 
communication between patients and physicians about medication adherence status; (2) 
medication non-adherence not being driven by personality or demographic 
characteristic; (3) patients’ information needs not always being met; (4) inconsistency in 
healthcare providers’ communication about prescription medication; and (5) medication 
non-adherence being a rational behavior that is based on a decision-making process. 
Given these prepositions, it was also hypothesized that patients hold different beliefs and 
attitudes about different medications and, hence, may adhere differently to different 
medication.  
According to the Proximal-Distal Continuum of Adherence Driver Model, the 
treatment-related beliefs and skills are the strongest drivers (i.e., proximal drivers) of 
medication non-adherence followed by the disease-related beliefs and skills (i.e., 
intermediate drivers), generic beliefs, health states, and skills (i.e., distal drivers), and 
sociodemographic characteristics (i.e., distal drivers) [28, 29]. The proximal drivers of 
medication adherence include perceived need for medications, perceived medication 
concerns, and perceived medication affordability. Although it is not depicted in the 
model, McHorney hypothesized that perceived need for medications and perceived 
medication concerns are stronger drivers than perceived medication affordability [28]. 
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Under the Proximal-Distal Continuum of Adherence Driver Model, proximal drivers are 
influenced largely by intermediate drivers, and intermediate drivers are largely 
influenced by distal drivers. Examples of intermediate drivers include patients’ 
knowledge of their condition and treatment, beliefs and attitudes about side effects, 
health information-seeking behavior, trust in their healthcare providers, and participation 
in their care.  Examples of distal drivers are demographic characteristics, as well as 
physical and mental health status, self-efficacy, and social support. 
The Proximal-Distal Continuum of Adherence Drivers Model overcomes the 
caveats of the traditional behavioral theories by combining the constructs from the 
traditional behavioral theories (e.g., necessity-concerns framework and Brenner’s 
proximal-distal continuum) and empirical evidence [28]. By assuming the linear 
relationship between the drivers, the model can suggest simpler models for analyses, but 
its ability to depict the real relationship between drivers (e.g., moderation or feedback 
loop) is limited. Furthermore, the model focuses heavily on patient-level factors.  
In this dissertation, an extended Proximal-Distal Conitnuum of Adherence 
Drivers Model was proposed (Figure 1). The extended model includes patient-provider 
relationships and healthcare system to depict the effects of these factors on medication 
adherence. In the extended model, it was hypothesized that patient-provider relationship 
can influence the generic, disease-related, and treatment-related knowledge, attitudes, 
and skills. The healthcare system can influence patient-provider relationship by 
influencing the training of healthcare providers or the potential of changing appointment 
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schedules. The extended model should provide a more holistic perspective of the 
medication non-adherence than the original model. 
 
Figure 1. Extended Proximal-Distal Continuum of Adherence Drivers Model 
 
 
1.5. Structure of Dissertation 
The remaining portion of this dissertation will describe three research papers that 
examine different factors associated with medication adherence in older adults using the 
extended Proximal-Distal Conitnuum of Adherence Drivers Model.  
The first paper used a systematic literature review and meta-analysis to describe 
the prevalence of medication non-adherence and overview the association between 
patient-provider relationship and medication non-adherence among community-dwelling 
older adults. To date, there is no review in the topic that specifically focuses on the older 
population. Also, there is limited knowledge of how different aspects of patient-provider 
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relationship or medical interaction are related to patients’ medication adherence. The 
first research paper attempted to fill the knowledge gap and add to existing knowledge 
by highlighting the current state of research. Understanding the differential effects of 
patient-provider relationship on medication adherence in the population will provide 
valuable evidence for program and policy developers to enhance the design of 
interventions.  
The second paper used multiple linear mixed-effects models to examine the long-
term impacts of the Chronic Disease Self-Management Program (CDSMP) on 
medication non-adherence in older adults. While CDSMP has shown to improve 
medication adherence in 12 months, there is inadequate evidence about how CDSMP 
influences medication adherence. The second research paper attempted to fill the 
knowledge gap by examining the relationship between long-term program impacts on 
medication adherence and different aspects of short-term program impacts (e.g., self-
rated health, depression, and communication with doctors).   
The third paper used structural equation modeling to examine the causal paths 
between poverty, patient attitudes, and cost-related medication non-adherence (CRN). 
Extant evidence indicates that CRN is influenced by both financial and non-financial 
factors. However, there is a limited understanding about how effects of financial factors 
on CRN may be further augmented or diminished by nonfinancial factors, such as 
patient satisfaction and perceived access to care. By exploring the modifiable, non-
financial factors, the study findings can inform public health and clinical practitioners 
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about a potential intervention point to improve medication adherence, especially among 
those with a greater financial burden.    
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2. MEDICATION ADHERENCE AND PATIENT-PROVIDER RELATIONSHIP 
AMONG COMMUNITY-DWELLING OLDER ADULTS: SYSTEMATIC 
LITERATURE REVIEW 
 
 
2.1. Overview 
Background:  Medication non-adherence is a public health problem that is related 
to various health-related outcomes and treatment inefficiency in patients. While patient-
provider relationship (PPR) is known to be associated with medication adherence, the 
magnitudes and directions of the association between different aspects of PPR and 
medication adherence are understudied. 
Objective: To describe the prevalence of medication non-adherence and 
overview the association between different aspects of PPR and medication adherence 
among community-dwelling older adults. 
Methods: Systematic search of literature from major databases with the key 
words, such as medication adherence and patient-provider relationship yielded 2,148 
articles. Of the articles retrieved from the literature search, 10 articles were included in 
this review.  
Results: Using a fixed-effects model, the mean prevalence rate of medication 
adherence was 67% (SE = 0.31; 95% CI = [66.53%, 67.75%]). The most frequently 
measured aspect of PPR was the instrumental dimension (i.e., task-oriented). A 
quantitative summary of the association between PPR and medication adherence was not 
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feasible due to the diversity of PPR definitions and measurements. Of the instrumental 
dimensions examined, information exchange was positively associated with medication 
adherence, but discussion about barriers was negatively associated with medication 
adherence. 
Conclusions: There is a high prevalence of medication non-adherence among 
community-dwelling older adults. Limited evidence suggests promoting effective 
information exchange between patients and providers can help attenuate the problem. 
More rigorous, longitudinal studies that use better measurements are needed to expand 
our understanding of the relationship between PPR and medication adherence. 
 
2.2. Introduction 
Patient-provider relationship (PPR) is one of the key drivers of medication 
adherence [1-3]. In a meta-analysis, Haskard-Zolnierek and Dimatteo [4] found a strong 
positive relationship between physicians’ communication and patients’ adherence to 
treatments. By examining the effects of physician communication interventions on 
patients’ treatment adherence, the meta-analysis suggested a potential causal link 
between the physicians’ communication and patients’ treatment adherence [4]. Other 
studies suggested positive associations between PPR and health literacy [5, 6], 
treatment-related attitudes [7], and patient satisfaction [8]. 
While the past research has suggested the positive relationship between better 
PPR and optimal treatment adherence [4], the evidence was still limited, and thus the 
causal effect was inconclusive. One of the reasons for the inconclusiveness is the 
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complexity in defining and measuring PPR. PPR describes a state of being connected, as 
well as the process of connecting patients and healthcare providers, which involves 
interactions of the two systems [9]. Ong et al. [10] described medical interactions in 
terms of purposes of medical interaction, types of interaction analysis models, and types 
of medical communication behaviors. According to Ong et al. [10], Medical interactions 
serve three purposes: to create a good interpersonal relationship, to exchange 
information, and to make medical decisions [10]. There are several approaches to 
analyze medical interactions, and the approaches can be described in terms of what they 
measure, clinical relevance, observational strategies, reliability and validity, and 
channels of communicative behaviors that it measures [10]. 
The interaction activities between patients and healthcare providers can be 
categorized into affective or instrumental behaviors, verbal or non-verbal behaviors, and 
high- or low-controlling behaviors [10]. The affective behavior type involves emotions, 
trust, respect, and empathy. On the other hand, the instrumental behavior type 
incorporates task-oriented behaviors, such as giving and seeking information and making 
treatment-related decision. Ong et al. [10] linked affective behavior type to the ‘care’ 
system, which reflects ‘patients’ need to feel known and understood,’ and instrumental 
behaviors to the ‘cure’ system, which reflects ‘patients’ need to know and understand.’ 
The high- or low-controlling behaviors are reflection of the power distribution 
between patients and their healthcare providers. The traditional PPR model is the 
paternalistic model, in which healthcare providers tend to lead the interactions and 
patients are appeared as recipients of care. More recent PPR models include patient-
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centered and shared-decision models, in which healthcare providers tend to show less 
controlling-behaviors and patients are appeared as partners or collaborators. Patients 
who worked in a partnership with their physicians were more likely be satisfied than the 
patients who engaged in the paternalistic relationship [11]. Past studies have also shown 
positive effects of the collaborative PPR in treatment adherence [12-14]. 
Understanding effects of the different aspects of PPR on medication adherence 
will enable the formulation of effective and efficient medical interaction strategies for 
improving medication adherence. Barlett et al. [15] suggested that magnitude of the 
correlation between affective behaviors and medication adherence (r=0.19) was greater 
than magnitude of the correlation between instrumental behaviors and medication 
adherence (r=0.03). The Barlett’s study implies a stronger relationship between affective 
interaction behaviors and treatment adherence in relative to the relationship between 
instrumental interaction behaviors and treatment adherence [15]. The past reviews 
related to the topic included diverse populations and broad medical treatments [4] and 
did not focus on older adults. There is a need for an overview of the empirical evidence 
to determine direction, size, and significance of the relationship between different 
components of medical interactions and medication adherence. 
The objectives of this systematic literature review are two folds. First, the review 
summarized the prevalence of medication non-adherence among community-dwelling 
older adults. Second, the review attempted to provide an overview of the association 
between the different aspects of PPR and medication adherence among community-
dwelling older adults in an outpatient setting. In this review, community-dwelling older 
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adults refer to older adults who live independently in a community and are not 
institutionalized. 
 
2.3. Methods 
2.3.1.Definitions 
For this literature review, medication adherence was defined as the extent to 
which an individual takes his or her medication as prescribed by a healthcare provider. 
The meta-analysis used a relatively-general definition to ensure inclusion of more 
studies as long as the studies examined at least one aspect of medication adherence (e.g., 
type of medication adherence or degree of medication adherence). Furthermore, the 
studies were not excluded from the current review based on the measurement types. 
Operational definitions for medication adherence included self-reported measures, 
Medication Possession Ratio (MPR), pill counts, biochemical assessment, and electronic 
monitors. Good medication adherence is typically defined as at least 80% of MPR or not 
missing any dose during an observed period of time. Provider-patient relation (PPR) 
was defined as the instrumental or affective interactions. Examples of the instrumental 
interactions included decision-making and information exchange. Examples of the 
affective interactions included trust and feeling of being understood. PPR can be 
measured from provider’s and/or patient’s perspectives surveys or from a third-person’s 
observation. 
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2.3.2.Literature Search 
The literature search was conducted in three electronic databases: PsycInfo, 
Medline (Pubmed), and Scopus with Boolean connections using the key words, such as 
prescription, adherence or compliance, and patient physician relationship, interaction, 
communication, shared decision making, or trust. The search terms were determined 
through a preliminary literature search, consultation with a librarian, and a discussion 
among the authors (SL, MO, DD, AH, and LJ). As a complimentary search strategy, the 
primary reviewer (SL) conducted reference searches of the identified articles to identify 
additional papers. 
 
2.3.3.Literature Selection 
Each identified paper was screened for its relevance based on a set of pre-
determined inclusion and exclusion criteria. Papers were included if the papers were: (1) 
written in English; (2) having at least one quantitative result; (3) examining the 
association between PPR and medication adherence; and (4) published in 2007 or after 
(no more literature was searched after July 22nd, 2017). Studies were excluded if any of 
the following exclusion criteria was met: (1) focusing on population younger than 50 
years old; (2) not focusing on provider-prescribed medications; (3) not focusing on self-
administered medications; (4) not focusing on oral medications (e.g., eye drop and 
inhaler); (5) focusing on short-term conditions; (6) focusing on populations with or 
medications for cognitive limitations, psychiatric symptoms, or substance abuse; (7) 
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focusing on communicable diseases; (8) focusing on institutionalized population; or (8) 
theoretical research, literature reviews, or utilizing only qualitative research methods. 
The screening was performed on the papers’ titles, abstracts, and then on their 
full texts. Two reviewers (SL and AY) independently scanned the randomly-selected 
10% of the papers generated by the search based on the inclusion and exclusion criteria. 
If the titles did not provide sufficient information to decide the inclusion status, the 
papers’ abstracts were scanned. Similarly, if the abstracts did not provide sufficient 
information to decide the inclusion status, the papers’ full texts were scanned. The two 
reviewers compared their decisions about the inclusion status of the scanned papers and 
reached consensus. In the next step, the primary reviewer (SL) screened all remaining 
identified papers. 
 
2.3.4.Quality Assessment 
A quality assessment checklist was constructed based on the National Heart, 
Lung, and Blood Institute’s quality assessment tool for observational cohort and cross-
sectional studies [16], Effective Public Health Practice Project tools [17], and Critical 
Appraisal Skills Programme tools [18]. The two reviewers (SL and AY) independently 
reviewed the quality of the selected papers using the constructed quality assessment 
checklist. The two reviewers compared their quality assessment decisions and reached a 
consensus. Most of the selected studies included only a single cohort, and hence the item 
number 8 (i.e., if there was more than one cohort, were all the subjects selected or 
recruited from the same or similar populations (including the same time period)?) was 
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not applicable. Thereby, the mean of the twenty remaining items were used as the 
overall quality score. 
Table 1. Quality assessment checklist 
Table 1. (Continued) 
No Criteria Scoring 
1 Was the research question or objective in this paper clearly 
stated? 
Yes = 1,  
No or Not Reported = 0 
2 Was the study population clearly specified and defined? 
(Demographics) 
Yes = 1,  
No or Not Reported = 0 
3 Was the study population clearly specified and defined? 
(Location) 
Yes = 1,  
No or Not Reported = 0 
4 Was the study population clearly specified and defined? (Time 
period) 
Yes = 1,  
No or Not Reported = 0 
5 Were the individuals selected to participate in the study likely 
to be representative of the target population? 
Yes = 1,  
No or Not Reported = 0 
6 Was there any significant difference between those who 
participated in the study and those who did not participate in 
the study? 
Yes or Not Reported = 0,  
No = 1 
7 Was the participation rate of eligible persons at least 50%? (% 
of those who participated from total number of reached for 
recruitment) 
Yes = 1,  
No or Not Reported = 0 
8 If there were more than one cohort, were all the subjects 
selected or recruited from the same or similar populations 
(including the same time period)?  
Yes = 1,  
No or Not Reported = 0 
9 Were inclusion and exclusion criteria for being in the study 
prespecified and applied uniformly to all participants? 
Yes = 1,  
No or Not Reported = 0 
10 Was a sample size justification, power description, variance, or 
effect estimates provided? 
Yes = 1,  
No or Not Reported = 0 
11 For exposures that can vary in amount or level, did the study 
examine different levels of the exposure as related to the 
outcome (e.g., categories of exposure, or exposure measured as 
continuous variable)? 
Yes = 1,  
No or Not Reported = 0 
12 
Were measure(s) of PPR clearly defined? 
Yes = 1,  
No or Not Reported = 0 
13 
Were the tools or methods used to measure PPR valid? 
Yes = 1,  
No or Not Reported = 0 
14 
Were the tools or methods used to measure PPR reliable? 
Yes = 1,  
No or Not Reported = 0 
15 
 Were measure(s) of medication adherence clearly defined? 
Yes = 1,  
No or Not Reported = 0 
16 Were the tools or methods used to measure medication 
adherence valid? 
Yes = 1,  
No or Not Reported = 0 
17 Were the tools or methods used to measure medication 
adherence reliable? 
Yes = 1,  
No or Not Reported = 0 
18 Were multiple tools or methods used to measure medication 
adherence? 
Yes = 1,  
No or Not Reported = 0 
19 Were key potential confounding variables measured and 
adjusted statistically for their impact on the relationship 
between PPR and medication adherence? 
More than 
sociodemographic factors = 
2, At least 
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Table 1. (Continued) 
No Criteria Scoring 
(Key confounding variables included but not limited to: 
income, out-of-pocket cost, patient beliefs & attitudes, regimen 
complexity, regimen duration, and depression) 
sociodemographic factors = 
1, No = 0 
20 
Were the statistical methods appropriate for the study design? 
Yes = 1,  
No or Not Reported = 0 
21 Were the methods for performing the analyses described in 
sufficient detail? 
Yes = 1,  
No or Not Reported = 0 
 
2.3.5.Data Extraction 
From the selected papers, the primary reviewer (SL) extracted the study 
characteristics (author(s), publication year, data source (e.g., primary or secondary data), 
study design, location where the study was conducted (e.g., country, state, city, or 
region), sample sizes, patient demographics, diagnostic characteristics, medication types, 
medication adherence variable(s), PPR variable(s), forms of data analysis, control 
variables, and measure of association between medication adherence and PPR). For 
medication adherence and PPR variables, definition of the measurements, types of 
measurement tools, levels represented (e.g., dose or intensity), dichotomization of 
variables, raters (e.g., patient, provider, researcher, or others), means or proportions, and 
standard deviations or variances were coded. If a study used more than one measure to 
index the same construct (medication adherence or PPR), each measure was coded 
separately. Furthermore, if the study reported the data for subsamples that were 
distinctively different by a characteristic that was commonly found in other studies (e.g., 
gender), the subsamples were treated as independent studies. However, if the subsamples 
were different by a characteristic that was not commonly found in other studies (e.g., 
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have or do not have problem with medication cost), the data from the subsamples were 
pooled (e.g., using Mantel-Hetzel method for odd ratios). 
 
2.3.6.Effect Sizes 
The effect size calculation for the current review primarily followed the 
instruction from the book, Practical meta-analysis, by Lipsey and Wilson [19]. The 
effect size (ES), standard error of the effect size (SE), and the inverse variance weight of 
the effect size (w) were calculated for each of the commonly-reported participant 
characteristics (e.g., age, sex, and race). While not all ten selected studies reported race 
in an identical set of categories, the proportion of Whites could be obtained from the 
eight studies (80%). Of the eight studies, two studies did not include any Whites in their 
studies (i.e., proportion of zero). If proportions are less than 0.2 or greater than 0.8, the 
direct proportion effect size statistics (as used for sex) will overestimate the degree of 
heterogeneity and do not produce a reliable ES [19]. Thereby, the ES for race was 
estimated in logits and then was converted back to proportions for interpretations. The 
mean effect sizes for age, sex, and race were estimated by weighting the ES from each 
study by the w from the corresponding study. Other sociodegmographics (e.g., education 
and income) were not reported in comparable formats to calculate mean effect sizes.  
Most studies used either binary or dichotomized measure medication adherence. 
Hence, direct proportion effect size statistics was used as the ES. Under the assumption 
that the measures of medication adherence were comparable, heterogeneity of the ES 
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across the studies in terms of population characteristics or study country was examined 
using the Q-statistics (fixed-effects model). 
The measures of PPR varied significantly, and hence a summary or comparison 
across the reported measures of PPR was not feasible. Similarly, a summary or 
comparison of the association between medication adherence and PPR was not feasible 
due to the heterogeneity of the reported measures. Thereby, the descriptives of what 
constructs were measured, in what frequencies, and direction of the association (e.g., 
positive, negative, no difference, and unknown) were documented. All the procedures 
were performed using the Microsoft Excel and R. 
 
2.4. Results 
2.4.1.Study Characteristics 
Ten papers [20-29] were included in this review. The flow chart of the literature 
selection process was depicted in Figure 2 [30]. Detailed description of the ten selected 
studies were provided in Table A1 (Appendix A). All ten studies were cross-sectional 
studies, and eight out of the ten studies [21-26, 28, 29] were based on primary data. The 
selected studies were conducted at multiple geographic locations, including the US 
(70%) [20-24, 27, 29], Philippines (10%) [26], Brazil (10%) [25], and Republic of Korea 
(10%) [28] (Table A1). Of the ten studies, four focused on hypertension (40%) [21, 24, 
27, 29], one focused on diabetes (10%) [20], and other studies did not focus on any 
specific chronic conditions (50%) [22, 23, 25, 26, 28]. while one study (10%) failed to 
specify the provider type [27], other studies looked at patients’ relationship or interaction 
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with doctors or physicians (70%) [20-23, 25, 26, 29], pharmacists (10%) [28], or 
multiple provider types (e.g., doctors or nurses) (10%) [24]. 
Figure 2. Flow chart of literature selection process  
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The quality assessment score of the included studies ranged from 0.60 to 0.81 
(the quality assessment score ranged from 0 to 1, with a higher score indicating the 
better quality). A few methodological issues were identified (Table 2). All of the studies 
were based on the cross-sectional data, hence causality cannot be drawn from the study-
design or the data. Furthermore, all the studies either failed to report or reported 
statistically-significant differences between those who participated in the study and those 
who did not participate in the study. Only one of the included study provided sample 
size justification, power, variance, or effect estimate [27]. Most of the included studies 
(70%) used binary variables to report PPR and medication adherence [21-27]. 
Furthermore, none of the included studies used multiple methods to measure medication 
adherence. All the included studies used patients’ self-reported data for measuring 
medication adherence. Eight studies (80%) performed multivariate analyses after 
controlling for sociodemographic variables, as well as condition-, prescription-, or 
patients’ attitudes-related variables [20, 21, 23, 24, 26-29]. 
Table 2. Quality assessment results (Score ranges from 0 to 1 with a higher score 
indicating better study quality) 
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Table 2. (Continued) 
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18 0 0 0 0 0 0 0 0 0 0 
19 2 2 0 2 2 0 2 2 2 2 
20 1 1 1 1 1 0 1 1 1 1 
21 1 1 0 0 1 1 1 1 1 1 
Quality Score 0.8 0.7 0.6 0.7 0.8 0.6 0.6 0.7 0.7 0.8 
 
 
2.4.2.Participant Characteristics 
The ten selected studies included a total of 25,010 patients (Table 3). Of the ten 
selected, seven studies [20, 22, 24-28], in which both mean and standard deviation of 
age were obtainable, were used to estimate the mean age of the total participants. The 
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mean age was 71 years old (standard error [SE]= 0.02; 95% Confidence Interval [CI] = 
[70.75, 70.83]). The mean proportion of the female was 59% (SE = 0.31; 95% CI = 
[58.15%, 59.39%]), and the mean proportion of Whites was 82% (95% CI = 81.09%, 
82.20%). 
Table 3. Summary characteristics of the study participants from the studies included in 
the review 
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Age 
(Mean 
(SD)) 
69 
(8.7) 
66 
(NA) 
75 
(7.0) 
66 
(NA) 
77 
(5.5) 
70 
(7.8) 
70  
(0.38) 
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75 
(5.5) 
68 
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70 
(NA) 
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Primary 
Race 
White 
(70%) 
White 
(54%) 
White 
(88%) 
White 
(86%) 
Black 
(65%) 
White 
(53%) 
Asian 
(100
%) 
c 
Asian 
(100
%) 
White 
(60%) 
Female 54% d 59% 50% 66% 66% 62% 59% 70% 78% 
a = Mean and standard deviation were estimated based on reported frequency data: 61-70 (62.2%); 71-80 
(26.2%); 81-91 (11.7%).  
b = less than 65 (18%); 65-75 (49%); > 76 (33%). Mean and standard deviation could not be estimated, 
because the minimum and maximum ages were not specified. Therefore, mid-point of the median category 
was presented in the table.  
c = Proportion of primary race was not specified (African American (31%)). 
d = While the frequency or percentage was not provided, the authors indicated in the discussion that “we 
only studied regular users of the VA (Veterans Affairs) system, … the VA system cares primarily for male 
patients, so our results may not be generalizable to women…” 
 
 
2.4.3. Medication Adherence 
The reported prevalence of medication adherence ranged from 48% to 86% [20-
29]. Under the crude assumption that the different measures were comparable, the mean 
prevalence rate of medication adherence was 67% (SE = 0.31; 95% CI = [66.53%, 
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67.75%]). There was a statistically-significant difference in the prevalence rates of 
medication adherence across the studies (Q = 1535.00, df = 5 p < 0.05). There was a 
statistically-significant difference between the US and non-US countries (Qb = 29.27, df 
= 1, p < 0.05). The mean prevalence rate of medication adherence was 67% (SE = 0.31; 
95% CI = [66.76%, 67.99%]) in the US [20-24, 27, 29] and 55% (SE = 2.25; 95% CI = 
[50.70%, 59.51%]) in countries other than the US [25, 26, 28]. 
 
2.4.4. Patient-provider relationship 
Six of the selected studies (60%) measured the instrumental interaction [20-22, 
25, 28, 29], one (10%) measured the affective interaction [24], two (20%) measured 
patients’ trust in their physicians [23, 26], and two (20%) measured patients’ perception 
about their PPR in general [25, 28]. Of the six studies that measured the instrumental 
interactions, two (33%) examined information exchange-related interaction [28, 29] and 
one (17%) examined both information exchange-related interaction and patients’ 
involvement in decision-making [20]; two (33%) examined discussion of barriers [22] or 
making adherence easier [21]; and one (17%) examined frequency of patient-physician 
dialogue about health/treatment [25]. Due to the diversity of the operational definition of 
PPR, a summary statistic for PPR was not feasible. 
 
2.4.5. Association between Medication Adherence and PPR 
All three studies that measured information exchange-related interaction 
indicated positive relationship between the interaction type and patients’ medication 
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adherence [20, 28, 29]. All two studies that measured discussion of barriers or making 
adherence easier indicated negative relationship between the interaction type and 
patients’ medication adherence [21, 22]. Only one study [24] measured the affective 
interaction, and the study did not find any meaningful relationship between the 
interaction type and patients’ medication adherence. The two studies about the 
relationship between trust and medication adherence were not comparable or summable 
due to the remarkably-distinct measures of medication adherence (e.g., general 
medication adherence versus cost-related medication adherence) [23, 26].  According to 
the study by Donohue et al.[23], there wasn’t any meaningful relationship between trust 
and cost-related medication adherence. On the other hand, Guz et al.[26] observed a 
significant and strong relationship between patients’ trust in their physicians and 
medication adherence in Philippine. 
 
2.5. Discussion 
The current review examined the relationships between medication adherence 
and PPR for 25,010 patients across ten studies [20-29]. The prevalence of medication 
adherence was about 67%, and was lower in non-US countries comparing to the US 
(55% versus 67%). The selected studies examined diverse forms of PPR, and 
instrumental interaction (e.g., information exchange and decision-making) was most 
frequently examined form of PPR. 
The prevalence of medication adherence reported in the literature varied 
significantly across the literature. For example, a review of the antihypertension 
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medication non-adherence among patients with treatment-resistant hypertension varied 
from 3.3% to 86.1% with the average of 31.2% [31]. The pooled medication adherence 
rate from the review by Durand et al.[31] was comparable to the finding from the current 
review (medication adherence rates of 67%, which is equivalent to medication non-
adherence rates of 33%). Furthermore, the current review also indicated that the 
medication adherence was poorer in non-US countries (i.e., Brazil, Philippine, and 
Korea). This finding is also consistent with the recent meta-analysis conducted by 
Abegaz et al.[32]. Abegaz et al.[32] focused on the prevalence of non-adherence to 
antihypertensive drugs among adults, and found that the proportion of non-adherence 
was to higher in the studies conducted in Africa and Asia relative to American and 
European studies. A potential explanation to the observed finding may be related to 
cultural difference. For example, use of complementary or alternative medicine may be 
associated with lower medication adherence in older adults [33]. 
The current review indicated that while general information exchange had a 
positive association with medication adherence, discussion with providers about cost-
related barriers or how to make the adherence easier had a negative association with 
medication adherence. A plausible explanation for the observations is the ‘context.’ For 
example, the discussion with healthcare providers about cost-related barriers might have 
occurred more frequently among those who had poorer health outcomes, or who were 
thought to have poorer medication adherence by their healthcare providers. This 
explanation, furthermore, highlights the limited ability of the extant literature in drawing 
the causality between medication adherence and PPR. The relationship between PPR and 
 36 
 
 
medication adherence may not be linear, but non-linear (e.g., cyclical relationship) and 
need more complex dynamic systems perspective in future research.  
The current review has a few limitations. First, the number of selected studies in 
the current review was small, and there was too much heterogeneity with regard to the 
operational definitions to draw a summary or perform a comparison of the association 
between medication adherence and the different forms of PPR. Second, all studies 
included in the review used self-reported measure of medication adherence. None of the 
studies used multiple measures of medication adherence, as recommended in the 
literature [34, 35]. Third, all studies included in the review measured PPR from the 
patients’ perception. While patients’ perceived PPR provides a meaningful insight, it is 
desirable to examine PPR from the healthcare providers’ perceptions, as well as the 
symmetry between patients’ and providers’ perceptions about their relationship. 
 
2.6. Summary and Future Implication 
The finding from the current review indicates a significant medication non-
adherence problem among older adults and highlights the association between 
medication adherence and PPR. Promoting patients and providers about effective 
information exchange will produce desirable outcomes associated with improved 
medication adherence. While the extant literature provides the rich information about the 
potential association between the two constructs, the evidence is weak. Also, diversity of 
operational definitions of PPR and medication adherence, which has been a persistent 
issue in this topic of research, prevent or limits comparison across studies. As 
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recommended by Lam and Fresco [35], future research should balance reliability and 
practicability of the measures and use multiple measures to index medication adherence. 
Furthermore, inclusion of the time components in a research design will enhance the 
study’s capability to explain the causality beyond association. 
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3. EFFECTS OF CHRONIC DISEASE SELF-MANAGEMENT PROGRAM ON 
MEDICATION ADHERENCE AMONG OLDER ADULTS 
 
 
3.1. Overview 
Background: Older adults account for almost one-third of all medication 
prescribed in the US. Of special concern are the high rates of medication non-adherence 
in this population. Despite many interventions to promote medication adherence, we 
know little about the process of achieving medicarion adherence in older adults. 
Objective: The purpose of this study was to examine the long-term program 
impacts on medication adherence from participating in the Chronic Disease Self-
Management Program (CDSMP). 
Methods: Secondary data from the national CDSMP evaluation was used in this 
study. The secondary data included CDSMP participants’ sociodemographic 
characteristics, as well as their baseline and 6-month and 12-month follow-up 
assessments on health and health-related indicators, including medication adherence, 
self-rated health, depression, and patient communication with doctors. This study 
included those who were 65 years or older, had one or more chronic conditions, and 
attended at least the first or second session. Linear mixed models were used to analyze 
the impact of the short-term changes (i.e., 6 months) in self-rated health, depression, and 
patient communication skills on the long-term changes (i.e., 12 months) in intentional 
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and unintentional medication non-adherence. The subset analysis was performed among 
the participants with self-rated major depression at the baseline.  
Results: This study included 687 participants. On average, participants were 74.8 
years old and had about three chronic conditions. The majority of the participants were 
females (83.4%). Self-reported medication adherence did not improve significantly at 
the 6-month follow-up assessment (p=0.5184) but significantly-improved at the 12-
month follow-up assessment (p=0.0214). Among those with self-reported major 
depression at the baseline assessment, the short-term improvements in depression was 
associated with the decrease in unintentional medication non-adherence (p=0.0021) and 
the short-term improvements in self-rated health was associated with the increase in 
intentional medication non-adherence (p=0. 0447) at the 12-month follow-up 
assessment. 
Conclusions: The long-term impact of CDSMP on medication adherence was 
influenced by the short-term program impacts on depression and self-rated health. 
However, this mechanism provided only a limited explanation for the observed 
improvements in medication adherence. Medication non-adherence is a complex 
problem that is rooted in multiple inter-related factors. Future research are needed to 
understand the underlying complexity and guide the future interventions. 
 
3.2. Introduction 
Prescription medication has been increasingly used in management of chronic 
diseases, and especially older adults, who experience more chronic diseases than the 
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younger population. Medication use in older adults accounts for almost one-third of all 
medication prescribed in the US [1]. With the growth of the older adult population, the 
use of prescription medication and associated costs are expected to rise substantially in 
the future. Based a national report on health status, the use of one or more prescription 
drug among older adults had increased from 74% in 1988-1994 to 90% in 2009-2012 
[2]. Also, a use of five or more prescription drug among older adults had increased from 
14% in 1998-1994 to 39% in 2009-2012 [2]. In 2015, the US spent an estimated $457 
billion on prescription medications, accounting for about 17% of the total US healthcare 
costs [3]. The rise in expenditure on prescription medication is projected to exceed the 
growth in total healthcare expenditure [3]. Of special concern are the high rates of 
medication non-adherence in older population (e.g., about 40% being nonadherent based 
on the CMS data) [4]. Poor medication adherence is associated with treatment 
ineffectiveness, poorer clinical outcomes, and increased healthcare costs [5-8]. 
Based on the vigorous reviews of the literature review about the interventions for 
supporting medication adherence, complex interventions with multiple components had 
a greater likelihood of improving medication adherence for the patients with one or more 
long-term conditions [9, 10]. However, even the most successful intervention was not 
very effective [9, 10].  Furthermore, complexity of the interventions decreases the 
likelihood of successful translation of the interventions and make it difficult to identify 
the essential components of the interventions that are keys to the program successes. In 
addition, there has been a limited understanding about how each intervention component 
contributes in improving medication adherence. Filling these knowledge gaps is an 
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essential step to design a sustainable intervention for promoting medication adherence in 
older adults. 
This study attempted to expand the knowledge base by delving deeper and 
examining an intervention, Chronic Disease Self-Management Program (CDSMP), that 
has already been shown to be successful in improving medication adherence. CDSMP is 
a general self-management program that has already been successfully implemented 
among diverse populations in multiple settings. CDSMP is composed of six 2.5-hour 
sessions and covers a variety of topics, such as problem-solving skills, exercises, proper 
use of medication, communication skills, nutrition, and how to evaluate new treatment 
options [11]. CDSMP has been evaluated across 17 states over 6- and 12-month periods 
[11, 12]. From the baseline to 6-month follow-up, the program participants showed 
statistically-significant improvements in various health-related indicators (e.g., 
social/role activities limitation, depression, communication with doctor, self-rated 
health, pain, fatigue, and other health-related quality of life) [11]. At the 12-month 
follow-up, the program effects on self-rated health, fatigue, pain, depression, and 
communication with doctors were sustained [12]. Furthermore, statistically-significant 
improvements in medication adherence was observed at the 12-month follow-up 
assessment [12]. While Ory et al. [12] theorized that the long-term improvements in 
medication adherence could have been influenced by the short-term improvement in 
other health-related measures, the proposition has not been explored previously.  
Of the short-term program effects of CDSMP, self-rated health, depression, and 
communication with doctors are known to be associated with medication non-adherence. 
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There are strong, consistent evidence for the negative association between medication 
adherence and depression among diverse populations [13, 14]. For example, the negative 
association between medication adherence and depression was observed in patients with 
different chronic diseases, such as arthritis [15], diabetes [16-18], heart disease [19], and 
hypertension [20]. Thereby, improving depressive symptoms in short-term is expected to 
improve medication adherence in long-term. Furthermore, previous studies suggested 
potential moderating effects of baseline depressive symptoms on program impacts on 
various health-related indicators [21, 22].  
Self-rated health was associated with medication non-adherence in many past 
studies, but evidence has not always been consistent. In a study carried out in China, 
poor self-rated health was associated with worse medication adherence in patients with 
hypertension [23], and this result is consistent with the findings from other studies [24-
27]. A meta-analysis of 26 studies suggested that the relationship between patient 
adherence and health status depends on the seriousness of health conditions [28]. 
Communication with doctors is also acknowledged as an important correlate of 
medication non-adherence [4]. Thereby, it was hypothesized that the long-term 
improvements in medication adherence was influenced by the short-term improvements 
in self-rated health, patient communication, and depression (Figure 3). 
With the goal to explore and evaluate the long-term effects of CDSMP on 
medication adherence, this study examined the potential influence of short-term changes 
in self-rated health, depression, and patient communication on long-term improvements 
in medication adherence. Furthermore, a subset investigation was performed among the 
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participants who were at a greater risk of medication non-adherence (i.e., participants 
with major depression at the baseline measurement). 
 
Figure 3. Conceptual framework that describes the hypothesized process of how 
CDSMP influences long-term medication adherence 
 
 
 
 
3.3. Methods  
3.3.1. Data Source 
The secondary data from the national CDSMP evaluation [11, 12] was used for 
this study. Details of the study design and data collection procedure are available 
elsewhere [11, 12]. Briefly, the national CDSMP evaluation used a pre-post longitudinal 
design to assess the effects of CDSMP on various health and health-related indicators. 
CDSMP workshops were delivered to middle-aged and older adults by 22 organizations 
in 17 states between August 2010 and April 2011. The data was collected at the baseline 
and 6- and 12-months from the baseline. The collected data included the participants’ 
sociodemographic characteristics, health, depression, communication with their 
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physicians, medication adherence, and program attendance. All the data used in this 
study, other than attendance data, was self-reported by the participants using surveys. 
 
3.3.2. Study Participants 
The national CDSMP evaluation participant eligibilities were: (1) having at least 
one self-reported chronic condition, (2) participating in an English or Spanish CDSMP 
workshop, (3) attending at least the first or second session, (4) participating in a CDSMP 
workshop for the first time, (4) completing the baseline assessment, and (6) agreeing to 
participate in CDSMP evaluation. For this study, the study participants were further 
narrowed down to older adults (i.e., those who self-reported being 65 years old or older 
at the time of the baseline assessment). 
 
3.3.3. Variables 
Medication Adherence. 4-item Morisky Medication Adherence Scale (MMAS-
4) (also known as Medication Adherence Questionnaire) was used to measure 
medication adherence [29].  The MMAS-4 asked the following four items: (1) ever 
forget to take medicine, (2) ever have problems remembering to take medicine, (3) 
sometimes stop taking medicine when feel better, and (4) sometimes stop taking 
medicine when feel worse. Each item was scored “yes” or “no.” Participants who 
reported an affirmative response to any of the first two items were categorized as 
“engaging in unintentional medication non-adherence,” and the Cronbach’s alpha for the 
two-item scale was 0.64. Patients who reported an affirmative response to any of the last 
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two items were categorized as “engaging in intentional medication non-adherence,” and 
the Cronbach’s alpha for the two-item scale was 0.61. The average score of the four 
items was used as an indicator for the degree of medication adherence overall. The 
reliability of the MMAS-4, measured using the Cronbach’s alpha, was 0.56, and is 
similar to other studies [29, 30] 
Self-rated Health. A single item was used to examine the self-rated health: “in 
general, would you say that your health is excellent, very good, good, fair, or poor?” The 
response to the item ranged from “excellent” (=1) to “poor” (=5), with a lower score 
indicating better health. It is a standardized item used in multiple national surveys (e.g., 
National Health Interview Survey and Behavioral Risk Factor Surveillance System). 
Depression. The 8-item Patient Health Questionnaire (PHQ-8) was used as a 
measure of depression [31]. The PHQ-8 asked how often during the past 2 weeks the 
participants were bothered by: (1) little interest or pleasure in doing things; (2) feeling 
down, depressed, or hopeless; (3) trouble falling or staying asleep, or sleeping too much; 
(4) feeling tired; (5) poor appetite or overeating; (6) feeling bad bout self; (7) trouble 
concentrating on things; (8) moving or speaking slowly or being very fidgety or restless. 
Each item was scored “not at all” (=0), “several days” (=1), “more than half the days” 
(=2), or “nearly every day” (=3). The sum of the eight items were used as the composite 
score (ranging from 0 to 24, with a higher score indicating severer depression). A score 
of 10 or higher was considered major depression [31]. The reliability of the scale, among 
this study population was 0.81, measured using the Cronbach’s alpha. 
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Communication with Doctors. The following three items were used to assess 
what the participants do during their visits to their doctors: how often do you (1) prepare 
questions to ask; (2) ask questions; and (3) discuss personal problems. Each item was 
scored from “never” (=1) to “always” (=6). Mean of the three items was used as the 
composite score (ranging from 1 to 6, with a higher score indicating better 
communication with doctors) [32]. The Cronbach’s alpha, among this study population, 
was 0.78. 
Covariates. Participant’s self-reported information on age (years), sex, 
race/ethnicity, years of education (ranging from 1 to 23 years), number of sessions 
attended (ranging from 1 to 6), and number of chronic diseases were used in this study. 
Age was calculated by deducting the date of birth from the date of assessment. 
Participants were asked whether they were diagnosed with the following chronic 
diseases: Type 1 Diabetes, Type 2 Diabetes, asthma, chronic obstructive pulmonary 
disease (COPD), chronic lung diseases other than COPD, hypertension, heart disease, 
arthritis, cancer, depression, anxiety or other mental health condition, or any other 
chronic condition. The number of sessions attended were calculated by summing the 
total number of attended sessions out of the six available sessions. The number of 
chronic conditions was calculated by counting the affirmative responses to each self-
reported chronic condition. 
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3.3.4. Analysis 
The baseline characteristics of the study participants were described using mean 
and standard deviation for interval variables and frequency and percentage for 
categorical variables. Independent group comparisons (e.g., χ2 test for categorical 
variables and two-sample t-test for continuous variables) were used to compare the 
baseline characteristics of the participants with and without the 6- and 12-month follow-
up assessments.  
Next, multiple linear mixed models were performed to examine the changes in 
medication adherence over time (using SAS PROC MIXED and SAS PROC 
GENMOD). The first set of models were performed to examine the changes in 
medication adherences, self-rated health, depression, and patient communication from 
the baseline to 6- and 12-month follow-up assessments controlling for the covariates. 
The second set of models were performed to examine the changes in medication 
adherences from the baseline to 6- and 12-month follow-up assessments based on the 
baseline self-rated health, depression, or communication with doctors after controlling 
for the covariates. The last set of models were performed to examine the changes in 
medication adherence from the 6- to 12-month follow-up assessments based on the 
changes in self-rated health, depression, or communication with doctors from the 
baseline to the 6-month follow-up assessment after controlling for the covariates. The 
last sets of models were performed among the overall study population, as well as 
among the study population with major depression at the baseline assessment. 
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3.3.5. Institutional Review Board 
The secondary analysis of the data was approved by the Texas A&M University 
Institutional Review Board (IRB). 
 
3.4. Results 
3.4.1. Sample Characteristics 
This study included 687 participants who completed at least the baseline 
assessment. Table 4 shows the baseline characteristics of the study participants. In 
average, age of the study participants was 74.8 years old, years of education was 13, and 
number of chronic conditions was 2.9. The majority of the study participants was female 
(83.6%), non-Hispanic (82.8%), and White (60.6%) and attended at least 4 out of 6 
CDSMP workshop sessions (80.8%). At the baseline assessment, 18.1% of the study 
participants reported intentional medication non-adherence, and 38.0% reported 
unintentional medication non-adherence. 
Table 4 also shows the comparison between those who had the complete data and 
those who did not participate in the 6- or 12-month follow-up assessments. Of the 687 
study participants, 572 (83.3%) completed the 6-month follow-up assessment, and 512 
(74.5%) completed the 12-month follow-up assessment. Compared to the participants 
who did not complete the 6-month follow-up assessment, those who completed the 6-
month follow-up assessment were more likely to be Whites, had higher workshop 
completion rates, and reported more chronic conditions, better self-rated health, better 
depressive symptoms, and better communication with doctors. Similarly, compared to 
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the participants who did not complete the 12-month follow-up assessment, those who 
completed the 12-month follow-up assessment had higher workshop completion rates 
and reported better self-rated health and better depressive symptoms. 
 
Table 4. Characteristics of the study participants by follow-up assessment completion 
status 
 
 6-month assessments 12-month assessments 
Total 
(n=687) 
Completed 
(n=572) 
Not 
Completed 
(n=115)  
Completed 
(n=512) 
Not 
Completed 
(n=175)  
Mean 
(SD) or 
Freq 
(%) 
Mean (SD) 
or Freq 
(%) 
Mean (SD) 
or Freq 
(%) 
p-
value 
Mean (SD) 
or Freq 
(%) 
Mean (SD) 
or Freq 
(%) 
p-
value 
Age (years) 74.8 
(6.84) 
74.9 (6.83) 74.3 (6.90) 0.35 74.7 (6.77) 75.2 (7.06) 0.36 
Female 574 
(83.6%) 
476 
(83.2%) 
98 (85.2%) 0.60 426 
(82.6%) 
151 
(86.3%) 
0.26 
Non-Hispanic 563 
(82.8%) 
470 
(82.8%) 
93 (83.0%) 0.94 423 
(83.3%) 
140 
(81.4%) 
0.57 
White 416 
(60.6%) 
359 
(62.8%) 
57 (49.6%) <0.01* 315 
(61.5%) 
101 
(57.7%) 
0.84 
Education 
(years) 
13.0 
(3.73) 
13.0 (3.76) 12.8 (3.59) 0.72 13.0 (3.73) 12.8 (3.75) 0.51 
Number of 
chronic 
conditions 
2.9 
(1.59) 
3.0 (1.58) 2.6 (1.59) 0.02* 3.0 (1.53) 2.9 (1.75) 0.57 
Workshop 
completiona 
555 
(80.8%) 
488 
(85.3%) 
67 (58.3%) <0.01* 434 
(84.8%) 
121 
(69.1%) 
<0.01* 
Self-rated 
health 
3.1 
(0.90) 
3.0 (0.90) 3.2 (0.86) 0.03* 3.0 (0.89) 3.2 (0.91) 0.03* 
PHQ-8 5.3 
(4.62) 
5.1 (4.52) 6.3 (5.02) 0.01* 5.0 (4.42) 6.2 (5.08) <0.01* 
Communication 
with doctors 
2.7 
(1.36) 
2.7 (1.34) 2.3 (1.39) <0.01* 2.7 (1.37) 2.5 (1.34) 0.25 
MMAS-4 0.2 
(0.26) 
0.2 (0.26) 0.2 (0.26) 0.73 0.2 (0.25) 0.2 (0.26) 0.62 
Intentional 
medication non-
adherence 
124 
(18.1%) 
100 
(17.5%) 
24 (21.2%) 0.34 95 (18.6%) 29 (16.7%) 0.57 
Unintentional 
medication non-
adherence 
261 
(38.0%) 
218 
(38.1%) 
43 (37.4%) 0.88 199 
(38.9%) 
62 (35.4%) 0.42 
SD = standard deviation 
* Statistically-significant at alpha = 0.05.  
a. Attending at least 4 out of 6 CDSMP workshop sessions 
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3.4.2. Changes from Baseline to 6- and 12-month Follow-up Assessments 
Statistically-significant improvements in medication adherence was observed 
from the baseline to 12-month follow-up assessment, but not at the 6-month follow-up 
assessment (Table 5). The odds of engaging in unintentional medication non-adherence 
reduced significantly from the baseline to the 12-month follow-up assessment, but not at 
the 6-month follow-up assessment. Table 5 also shows the changes or ratios between the 
baseline to the 6- and 12-month follow-up assessments for self-rated health, PHQ-8, and 
patient communication. Compared to the baseline, the odds of reporting poorer self-rated 
health was lower at both 6- and 12-month follow-up assessments. Similarly, both PHQ-8 
and patient communication showed significant improvements from the baseline to the 6- 
and 12-month follow-up assessments. 
Table 5. Adjusted changes or ratio between baseline and follow-up medication 
adherence 
Health-related 
outcomes 
Baseline 
(n=687) 
6-month 
(n=572) 
12-month 
(n=512) 
Baseline to 6-
month 
Baseline to 12-
month 
Mean 
(SD) or 
Freq (%) 
Mean 
(SD) or 
Freq (%) 
Mean 
(SD) or 
Freq (%) 
Adjusted 
changes 
or ratioa 
p-
valuea 
Adjusted 
changes 
or ratioa p-valuea 
Self-rated 
health 
3.06 
(0.8966) 
2.96 
(0.8737) 
2.95 
(0.9118) 
0.78 0.0007* 0.77 0.0028* 
PHQ-8 5.31 
(4.6241) 
4.49 
(4.3191) 
4.20 
(4.3181) 
-0.74 <0.0001
* 
-0.97 <0.0001
* 
Patient 
communication 
2.65 
(1.3591) 
2.86 
(1.4146) 
2.89 
(1.4212) 
0.16 0.0019* 0.21 <0.0001
* 
Intentional 
medication non-
adherence 
124 
(18.1%) 
102 
(17.9%) 
86 
(16.8%) 
0.98 0.8904 0.92 0.5183 
Unintentional 
medication non-
adherence 
261 
(38.0%) 
200 
(35.0%) 
163 
(31.8%) 
0.88 0.1667 0.76 0.0057* 
MMAS-4 0.20 
(0.2559) 
0.19 
(0.2607) 
0.17 
(0.2461) 
0.01 0.5184 0.02 0.0214* 
SD = Standard deviation; * Statistically-significant at alpha = 0.05;  
a. Adjusted changes, ratios, and p-values were adjusted for age, sex, race/ethnicity, education, number of 
sessions attended, and number of chronic conditions. 
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3.4.3. Effects of Baseline Characteristics on Medication Adherence 
Baseline PHQ-8 score was significantly associated with changes in medication 
adherence from the baseline to the 6- and 12-month follow-up assessments (F2, 739 = 
3.83, p-value = 0.0222). Figure 4 shows change in medication adherence from baseline 
to the 6- and 12-month follow-up assessments by those with and without major 
depression at the baseline assessment. Both self-rated health and patient communication 
at baseline were not significantly associated with changes in medication adherence at the 
6- and 12-month follow-up assessments (p-value > 0.05). 
 
Figure 4. Changes in medication non-adherence from baseline to 6- and 12-month 
follow-up assessments among CDSMP participants with and without major depression at 
baseline (MMAS = Morisky Medication Adherence Scale) 
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Table 6. Effects of the baseline-to-6-month changes in self-rated health, PHQ-8, or 
patient communication on the changes in medication adherence between 6- and 12-
month follow-up assessments. [Regression coefficients for the interaction between time 
and the improvements after adjusting for the covariates (age, sex, race/ethnicity, 
education, number of attended sessions, and number of chronic conditions).] 
Improvements 
during the 
first 6 months 
(the baseline to 
6-month 
follow-up 
assessments) 
Overall (n=565) Major Depression (n=101) 
MMAS-
4 
Intentional 
Medication 
Non-
adherence 
Unintentional 
Medication 
Non-
adherence 
MMAS-
4 
Intentional 
Medication 
Non- 
adherence 
Unintentional 
Medication 
Non-
adherence 
Self-rated 
health 
-0.0006 0.0191 0.0527 -0.0073 0.9591* -0.1638 
PHQ-8 0.0012 0.033 -0.0470 -0.0077 0.0870 -0.1704* 
Patient 
communication 
0.0059 0.1580 0.0584 0.0053 0.0697 0.0116 
* Statistically-significant at alpha = 0.05; MMAS = Morisky Medication Adherence Scale 
 
3.4.4. Effects of the First 6-month Changes on the Following 6-month Changes in 
Medication Adherence  
Among the overall study population, the changes in self-rated health, 
communication with doctors, or PHQ-8 from baseline to 6-month follow-up assessment 
were not significantly associated with the changes in self-reported medication adherence 
from 6- to 12-month follow-up assessments) (p-value > 0.05) (Table 6). Among the 
study population with major depression at the baseline assessment, improvements in 
intentional medication non-adherence between the 6- to 12-month follow-up assessments 
was less for those who showed improvements in self-rated health (β = 0.9591, 95% CI = 
[0.0228, 1.8954], p-value = 0.0447) between the baseline and the 6-month follow-up 
assessment. Among the study population with major depression at the baseline 
assessment, the improvements in unintentional medication non-adherence during the 
final 6 months was greater for those who showed improvement in PHQ-8 (β = -0.1704, 
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95% CI = [-0.2792, -0.0616], p-value = 0.0021) during the first 6 months. All these 
regression results were adjusted for age, sex, race/ethnicity, education, number of 
attended sessions, and number of chronic conditions. 
 
3.5. Discussion 
In this study, the effects of CDSMP on medication adherence among the older 
participants was examined, and potential factors (e.g., baseline and first six-month 
changes in self-rated health, depression, and communication with doctors) that may 
contribute to the long-term changes in medication adherence among CDSMP 
participants was explored. Based on the extant literature, it was hypothesized that short-
term improvements in self-rated health, depression, and communication with doctors 
would contribute to the long-term improvements in medication adherence. The changes 
from the baseline to the 6-month follow-up assessment were considered as the short-
term changes, and the changes from the baseline to the 12-month follow-up assessment 
were considered as long-term changes. 
Confirming the prior CDSMP evaluation papers [11, 12], this study showed that 
CDSMP had a statistically-significant long-term effect on medication adherence but not 
short-term effects. Compared to the previously published CDSMP national evaluation 
papers [11, 12], which included participants at ages 19 years and above, this study 
focused specifically on older adults population. This study reaffirms that the impacts of 
CDSMP observed in a general population holds true for this specific age group. A 
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cognitive and behavioral intervention, such as CDSMP, may promote cognitive changes 
first, which then is followed by behavioral changes [33]. 
Furthermore, this study demonstrated that the program impacts primarily 
unintentional medication non-adherence rather than intentional medication non-
adherence. Unlike intentional medication non-adherence, unintentional medication non-
adherence is associated with lack of capacity or resources [34]. CDSMP educates its 
participants on skills and tools to handle stress, engage in healthy lifestyles, 
communicate with their family, friends, and physicians, and seek necessary resources. 
The acquirement of the skills and tools may be related to improvements in unintentional 
medication non-adherence, but not intentional medication non-adherence. Unintentional 
medication non-adherence is more prevalent in some health conditions, such as 
cardiovascular diseases [35], and the program may have particularly greater benefits 
among the population. 
It was also observed in this study that the program effect on medication 
adherence among the participants with major depression at the baseline assessment 
would be significantly-greater than those without major depression at the baseline 
assessment. Depression is one of the most consistent determinants of medication non-
adherence [13, 14]. Compared with the individuals without major depression, those with 
major depression are less likely to adhere to their medication at the baseline, hence more 
room for improvements. The finding implies that those with depressive symptoms can 
benefit more from CDSMP or similar programs with regard to adhering to their 
medication. 
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Among the participants with depressive symptoms, those who showed greater 
improvements in depression at the 6-month follow-up were more likely to show greater 
improvements in unintentional medication non-adherence from 6- to 12-month follow-
up assessments. As discussed previously, the literature have consistently indicated the 
positive association between depression and medication non-adherence [13, 14]. Also, 
depression is associated with poorer cognition [15, 36]. Given this, it is not surprising to 
find the strong association between the improvement in depression and improvement in 
unintentional medication non-adherence. In addition, the longitudinal nature of the 
current study adds to the literature by introducing the ‘time’ component and enabling 
ordering of events. On the other hand, the improvements in intentional medication non-
adherence during the final 6 months was less for the participants who showed 
improvement in self-rated health. Improved health can reduce perceived needs for the 
treatment, and thereby increasing the likelihood of intentional medication non-adherence 
[37, 38]. The perceived needs for the medication was higher among older adults who 
adherent to their medication treatments than those who reported intentional medication 
non-adherence [39]. 
There are some limitations to this study. First, the study relied on the self-
reported data. The self-reported data cannot be verified and may be subject to various 
biases (e.g., social desirability bias). In addition, the MMAS-4 had a relatively low 
reliability for this population. However, self-reported data can also provide a rich insight 
about the context. For example, self-reported data on medication non-adherence could be 
classified into intentional versus unintentional medication non-adherence. Second, this 
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study employed the secondary data analysis, and the study was limited by the 
availability of variables. The failure to include the important predictors in a regression 
analysis can lead to omitted variable bias and inaccurate statistical inferences. While the 
secondary data did not have all the key predictors of medication non-adherence (e.g., 
medication cost, patients’ attitudes toward medication, characteristics of prescription, 
and characteristics of providers), the data had a good number of the known predictors 
(e.g., self-rated health, depression, and communication with doctors) for the initial 
exploration. 
Despite the limitations, this study is one of the few studies that attempted to 
understand the underlying mechanism of the effect on medication adherence. Also, the 
secondary data was based on a pre-post longitudinal study design, hence allowed the 
examination of an over-time changes in the participants’ medication adherence, as well 
as other influencing factors (e.g., self-rated health, depression, and communication with 
doctors). 
 
3.6. Summary and Future Implication 
The current study attempted to examine the long-term effects of CDSMP on 
medication adherence that has not been examined in detail previously. This study 
suggests that CDSMP improves overall medication adherence in a long-term, and 
primarily unintentional medication non-adherence. Unintentional medication non-
adherence represents a primary form of medication non-adherence in older adults with 
one or more chronic conditions, and program such as CDSMP can be particularly more 
 62 
 
 
helpful among the population. This study also indicated that the long-term program 
impacts on medication non-adherence could be influenced through the short-term 
program impacts on other health and health-related indicators, such as self-rated health 
and depression.  The limitations of the current study guides the future research, such that 
future research can be further enlightened by a more comprehensive examination that 
incorporates the key drivers of medication adherence. 
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4. IMPACTS OF PATIENT’S ATTITUDES AND BELIEFS ON COST-RELATED 
MEDICATION NON-ADHERENCE AMONG OLDER ADULTS WITH 
CHRONIC DISEASES 
 
 
4.1. Overview  
Background: Cost-related medication non-adherence (CRN) can impact the 
management of chronic conditions prevalent in an aging population. Though patient 
attitudes have been identified as risk factors of CRN, limited data are available on 
interacting influences among poverty, patient attitudes, and CRN. The objective of this 
study was to examine the causal paths between poverty, patient attitudes, and CRN, 
based on the modified Proximal-Distal Continuum of Adherence Drivers Model. 
Methods: The study included a nationally-representative sample of 4,818 
individuals from the 2015 National Health Interview Survey data, 65-years or older, with 
the diagnosis of hypertension or diabetes and on prescription medication for at least one 
of these conditions. The structural equation modeling (SEM) was applied to the 2015 
National Health Interview Survey data to examine whether perceived medication 
affordability, access to healthcare, and patient satisfaction influence the effects of 
poverty on CRN (skipped doses, took less doses, or delayed filling prescription to save 
money). 
Results: The median age of the sample was 73-years, 55% were female, 92% 
were non-Hispanic, and 83% were White.  Six percent of the participants reported CRN 
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in the past 12-months. The model showed a good-to-fair fit, and all the paths were 
significant (p<0.05), except for age. The effects of poverty on CRN was mediated 
through the medication affordability, access to healthcare, and overall patient 
satisfaction. 
Discussion: The study examined the direct and indirect effects of patients’ 
attitudes, such as perceived medication affordability and patient satisfaction, on CRN 
and how patients’ attitudes medicated the effects of poverty on CRN. We call for more 
senior-friendly public health interventions that can address these modifiable barriers in 
order to reduce CRN in older adults with chronic conditions. 
 
4.2. Introduction 
Medication non-adherence is a persistent public health issue that can influence 
management of chronic conditions, especially among older adults who are more likely to 
bear a greater disease burden than their younger counterparts. While there are many 
reasons for medication non-adherence, older adults may forgo medications due to cost-
related concerns, such as prescription coverage and out-of-pocket costs [1-3]. This type 
of medication non-adherence is called cost-related medication non-adherence (CRN). 
CRN was observed in about ten to twenty percent of non-institutionalized older adults 
[4-6], and CRN was significantly more prevalent among older adults with 
multimorbidity (e.g., 43.1% among those with five or more chronic conditions versus 
13.7% among those without any chronic conditions) [4], as well as those who fell in the 
“doughnut-hole” [2]. Ample evidence from the literature implies the adverse 
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consequences of medication non-adherence, including poorer health, increased risk of 
mortality and greater healthcare costs [7-9]. 
Beyond the financial factors, past literature has also identified that CRN is 
associated with patients' characteristics (e.g., sociodemographic characteristics, health 
status, and attitudes) [10-12] and patients’ relationship with their healthcare providers 
[13]. For example, Kurlander et al. [14] examined CRN among patients with diabetes on 
diabetic and pain medications. Kurlander et al. [14] showed that low-income status was 
associated with CRN for pain medications but not for diabetes medications. The same 
study also showed that depressive symptoms and negative treatment-related beliefs were 
associated with CRN for diabetes medication. These observations imply that CRN is 
likely to be influenced by both financial and non-financial determinants. The effects of 
financial determinants on CRN may be further augmented or diminished by non-
financial factors, such as patients’ attitudes and beliefs. In this study, it was hypothesized 
that perceived medication affordability, access to healthcare, and patients’ satisfaction 
with healthcare services were drivers of CRN among older adults with chronic diseases. 
Patient satisfaction is an attitude associated with evaluation of patient’s 
experience with healthcare services [15, 16]. Mpinga and Chastonay [17] proposed that 
the major constructs of patient satisfaction include availability of services, accessibility 
of care (i.e., physical, economic, and information accessibility), participative healthcare, 
acceptability of cost (i.e., financial, physical, and cultural), and quality of care (e.g., 
competency and appropriate treatment and infrastructure). A comprehensive systematic 
review concluded that a positive association exists between patient satisfaction and 
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medication adherence [18]. However, the review used a broad definition of patient 
satisfaction and did not examine how each of the constructs of patient satisfaction was 
related to medication adherence. Also, there is a lack of understanding of the association 
between patient satisfaction and medication adherence. 
Medication affordability, a major construct of patient satisfaction [17], is a 
proximal driver of medication non-adherence under the Proximal-Distal Continuum of 
Adherence Drivers Model [19]. Based on a nationally-representative sample of adults 
with one or more chronic diseases, the odds of engaging in medication non-adherence 
among those with low medication affordability was almost four-times the odds of those 
with high medication affordability [19]. While medication affordability can be closely 
associated with diverse financial pressures (e.g., cost and resource availability), a study 
showed that medication affordability is not necessarily bound by the cost of prescription 
medication or financial resource availability [20]. 
Unlike medication affordability, relationship between medication adherence and 
physical access to healthcare has been under-studied. Based on the currently-available 
literature, physical access to care may have some, but relatively-weak effects on CRN. 
For example, previous studies showed conflicting findings about the relationship 
between the distance to a healthcare location (e.g., clinic or hospital) and medication 
adherence. A study did not find any statistically-significant relationship between 
treatment compliance and physical access to healthcare among pediatric kidney 
transplant population [21], but another study reported that the distance to clinic was a 
statistically-significant contributing factor to medication non-adherence in diabetic 
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patients [22]. Long waiting time for meeting with healthcare providers was found to be 
associated with medication non-adherence among patients with hypertension and 
diabetes in South India [23]. The difference in the studies may be related to different 
characteristics of the study population and diverse aspects of physical access to 
healthcare. 
In this study, the potential causal paths involving poverty, patient attitudes, and 
CRN were hypothesized based on the modified Proximal-Distal Continuum of 
Adherence Drivers Model [19]. The model hypothesized that overall patient satisfaction, 
perceived access to care, and perceived medication affordability will mediate the 
relationship between CRN and the distal driver (e.g., household poverty level and age), 
and mental health. Furthermore, the modified model also hypothesized that (1) low 
financial resources would adversely affect perceived medication affordability, access to 
care, and CRN; (2) improving perceived medication affordability or access to care would 
increase patient satisfaction; (3) poorer mental health would adversely affect perceived 
medication affordability and CRN; (4) older age would adversely influence medication 
affordability and access to healthcare; and (5) the strongest predictor of the CRN would 
be perceived medication affordability. Thus, the objectives of this study are to examine 
the effects of patient attitudes on CRN and to examine the mediating effects of patient 
attitudes on relationship between poverty and CRN. 
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4.3. Methods 
4.3.1. Data Source 
The data source for this research is the National Center for Health Statistics 
(NCHS)’s National Health Interview Survey (NHIS) was collected in 2015. The NHIS 
2015 is a cross-sectional household interview survey that was designed to capture health 
and health-related information among the civilian noninstitutionalized population living 
in US at the time of assessment. The NHIS was collected via face-to-face interviews in a 
nationally-representative sample of households that had been sampled through a 
complex sampling design involving the use of an all-area sampling frame, state 
stratification, and differential sampling rates. The multistage sampling methods enabled 
the NCHS to be cost-efficient, yet still be able to select the representative sample of the 
target population. Furthermore, older black, Hispanic, and Asian adults (i.e., 65 years or 
older) had greater likelihood to be selected for the interview. 
 
4.3.2. Study Participants 
The target population of the NHIS 2015 was civilian noninstitutionalized 
populations living the US at the time of assessment, and the study participants were 
further narrowed down to those who self-reported: (1) being diagnosed with 
hypertension or diabetes; (2) having prescription medication for those conditions; and 
(3) being 65 years old or older at the time of the assessment. The survey participants 
were excluded from the study if the information about the sample adult was collected 
from a proxy. The study sample selection was performed based on the self-reported data. 
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4.3.3. Variables 
CRN. Data were collected on three types of the CRN behaviors in the past 
twelve months: skipping medication doses to save money, taking less medicine to save 
money, or delaying filling a prescription to save money. Each of the three items was 
scored “yes” or “no.” A patients who reported an affirmative response to any of the three 
items was categorized as “having CRN”, and patients who did not report any affirmative 
response to all three items were categorized as “not having CRN.” Reliability of the 
measures was tested, and it was shown that high test-retest reliability (i.e.,𝜅 ≥ 0.6) [24]. 
These are also standard measures used in national surveys such as NHIS and Medicare 
Current Beneficiary Survey. 
Medication unaffordability. Medication unaffordability was assessed using a 
single-item that asked: “during the past twelve months, was there any time when you 
needed (prescription medicines) but didn’t get it because you couldn’t afford it?” The 
item was scored “yes” or “no.” 
Overall patient satisfaction. Patient satisfaction was assessed using a single-
item that asked: “In general, how satisfied are you with the healthcare you received in 
the past twelve months?” The valid response ranged from “very satisfied” to “very 
dissatisfied,” with a higher score indicating greater satisfaction. Twenty-six (0.5%) of 
the study-eligible patients did not report on this variable because they did not receive 
any healthcare in the past twelve months. 
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Limited accessibility to care. Data were collected on the following five areas of 
accessibility to care in the past 12 months: (1) delayed getting care because of difficulty 
in getting through on the telephone; (2) delayed getting care because of difficulty in 
getting an appointment in a timely manner; (3) delayed getting care because of long wait 
times (at the healthcare setting); (4) delayed getting care because the (clinic/doctor’s) 
office wasn’t open when (the respondents) could get there; and (5)  delayed getting care 
because of lack of access to transportation. Each item was scored “yes” or “no.” A 
patient who reported “yes” to any of the five items was categorized as “experiencing 
poor accessibility to care,” and a patient who reported “no” to all five items was 
categorized as “not experiencing poor accessibility to care”. These are standard 
measures used in NHIS to examine accessibility to care since 1990s. 
Financial resource. The ratio of family income to the poverty threshold was 
used to account for the total household size. The ratio of family income to the poverty 
threshold was categorized into four groups: less than 1.00, 1.00 – 1.99, 2.00-3.99, and 
4.00 and over (based on 2014 poverty thresholds). 
Mental health. The 2015 NHIS used the K6 screening scale for assessing the 
presence of serious mental illness (SMI). The K6 screening scale is composed of six 5-
point Likert-items on how often respondents felt nervous, hopeless, restless or fidgety, 
depressed, needing effort on everything, and worthless in the past thirty days. For each 
item, the possible response ranged from “all of the time” (=1) to “none of the time” (=5), 
hence sum of the six K6 items could range from 6 to 30. Using the dichotomous scoring 
approach, as presented by Kessler et al. [25], the respondents with the sum of the K6 
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items being less than 19 were classified as “probably not having SMI” (=0), and the 
respondents with the sum of the K6 items being 19 or higher were classified as 
“probably having SMI” (=1). The Cronbach’s alpha for the scale was 0.84. 
Demographic and sociodemographic information. The 2015 NHIS data 
included age, sex, race, ethnicity, education, and self-rated health. The age was 
categorized into “less than 75-years” or “75-years or older.” The dichotomization was 
guided by the data distribution, such that about half of the study sample was assigned in 
each category. Sex was classified as male versus female. Ethnicity was dichotomized as 
Hispanic versus non-Hispanic. Race was dichotomized as White versus non-White. 
Region was categorized into Northeast, Midwest, South, and West. 
 
4.3.4. Analysis 
Mean and standard deviation or frequency and percentage were used to describe 
characteristics of the study participants and examine missing data. Twenty-six percent 
(n=1,254) of the study-eligible patients had missing values on one or more of the 
variables included in the structural equation model (SEM). Overall, there were very few 
missing values (<5%) with most variables, but eighty-five percent (n=1,063) of these 
patients did not report all the income-related information to estimate the financial 
resources. Thereby, the final hypothesized model was also tested using multiple 
alternative measures of financial resources (e.g., ever concerned about having not 
enough food in the past twelve months) that had relatively lower missing rates. The 
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result was not presented in this paper, but there was no meaningful difference between 
the analysis using the income variables and alternative variables. 
Using 𝜒2 test, being 75 and older, female, or non-White, living in Midwest, not 
having problem with access to healthcare, or having a SMI were positively associated 
with having one or more missing values on the SEM variables (p<0.5).  Similarly, being 
75 and older, female, or non-White, or living in Midwest were positively associated with 
missing data on poverty (p<0.5). 
Structural equation modeling (SEM), after conducting the preliminary analyses, 
was used to test the hypothesized model. The conventional SEM steps were followed: 
model identification, parameter estimation, fit evaluation, and model re-identification. 
Robust maximum likelihood estimation method was used to account for non-normal, 
categorical endogenous variables. Chi-square test, confirmatory factor index (CFI), root 
mean square error of approximation (RMSEA), and standardized root mean square 
residual (SRMR) were used for the fit evaluation. Non-significant Chi-square test, CFI 
above 0.95, RMSEA less than 0.05, and SRMR less than 0.05 were considered as an 
indication of a good-fit. RMSEA between 0.05 and 0.08 was considered as an indication 
of a fair-fit.  Furthermore, modification indices were used to identify potential areas of 
the model that were poorly-fitting. The direct path between access to healthcare and 
CRN was dropped to obtain the better fit.  
The final model for testing included a total of three exogenous variables (i.e., 
age, mental health, and poverty) and four endogenous variables (i.e., CRN, overall 
patient satisfaction, perceived access to care, and perceived medication affordability) 
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(Figure 5). The model was identified, because the model fulfilled the necessary 
condition for the model identification, t-rule (i.e., 𝑡 ≤ (𝑝)(𝑝 + 1)/2, where t = number 
of parameters to be estimated, and p=number of observed variables), and the recursive 
rules (i.e., no loops, no reciprocal causes among endogenous variables, and no correlated 
errors). 
 
Figure 5. Hypothesized model depicting factors influencing cost-related medication 
non-adherence 
 
 
All statistical analyses in this study were performed with SAS 9.4. As instructed 
in the NHIS data guide, the subset analyses were performed using the complete data file 
to ensure correct estimation of variance and use of appropriate sampling weights. 
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4.3.5. Institutional Review Board 
It has been confirmed from the Texas A&M University Institutional Review 
Board (IRB) that the study does not require any IRB approval for using a public use data 
set (https://vpr.tamu.edu/compliance/rcc/irb/irb-guidance/public-use-data-sets). 
 
Table 7. Characteristics of the study participants (weighted by sampling weights).  
Characteristics Weighted Median  
Age (years) 73 
 Weighted % 
Female 54.7 
Non-Hispanic 91.7 
Race  
 White 83.0 
 Black/African American 11.1 
 Asian 4.0 
 Other races 0.6 
 Multiple races 1.3 
Married or living with a partner 55.9 
Region  
 Northeast 18.9 
 Midwest 23.0 
 South 39.5 
 West 18.6 
Having diagnosed with hypertension only 38.1 
Having diagnosed with diabetes only 5.0 
Having diagnosed with both hypertension and 
diabetes 
26.7 
Cost-related medication non-adherence (CRN) 6.0 
 
 
4.4. Results 
4.4.1. Study Participants 
The final study sample included 4,818 older adults with hypertension or diabetes. 
Six percent of the study sample reported CRN in the past twelve months. The median 
age of the study sample was 73-years old, and the majority were female (54.7%), non-
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Hispanic (91.7%), and White (83.0%) (Table 7). Forty-two percent of the sample were 
married or lived with a partner at the time of assessment. 
 
4.4.2. Model Fit 
The tested model had a good-to-fair fit based on the three fit indices: CFI 
(0.9709), RMSEA (0.0588), and SRMR (0.0259). The Chi-square test was statistically-
significant (Chi-square = 66.6741, df = 5, p < 0.0001), which indicates a poor-fit. 
However, Chi-square test of fit can be sensitive to trivial deviations from the perfect-fit 
with a sufficiently-large sample size. Despite the adequate fit of the model, CRN 
remained largely unexplained with about 34.3% of the explained variance. 
4.4.3. Path Coefficients 
Table 8 and Figure 6 present the standardized path coefficients of the tested 
model. Greater likelihood of CRN was associated with poorer perceived-medication 
affordability (𝛽 = 0.55), lower patient satisfaction (𝛽 = -0.06), less financial resources (𝛽 
= -0.0720), and presence of SMI (𝛽 = 0.0442). Poor perceived medication affordability 
was associated with perceiving difficulty in access to care (𝛽 = 0.1259), lower ratio of 
family income-to-poverty threshold (𝛽 = -0.1209), presence of SMI (𝛽 =0.1051), and 
younger age (𝛽 = -0.0683). Lower patient satisfaction was associated with poorer 
perceived medication affordability (𝛽 = -0.0988), poorer perceived access to care (𝛽 = -
0.1423), and less financial resources (𝛽 =0.1090). Poorer perceived access to care was 
associated with less financial resources (𝛽 = -0.1250). Effects of age on perceived access 
to care was not statistically-significant (p = 0.8390). 
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Table 8. Standardized path coefficients 
 
Paths Standardized 𝜷 Standard error p-value 
Medication unaffordability → CRN 0.5500 0.0118 <.0001 
Overall satisfaction → CRN -0.0633 0.0138 <.0001 
Financial resource → CRN -0.0720 0.0139 <.0001 
SMI → CRN 0.0442 0.0138 0.0013 
Limited access to care → Medication 
unaffordability 
0.1259 0.0163 <.0001 
Financial resource → Medication 
unaffordability 
-0.1209 0.0166 <.0001 
SMI → Medication unaffordability 0.1051 0.0164 <.0001 
Age (Being 75 years or older) → Medication 
unaffordability  
-0.0683 0.0164 <.0001 
Medication unaffordability → Overall 
satisfaction 
-0.0988 0.0165 <.0001 
Limited access to care → Overall satisfaction -0.1423 0.0164 <.0001 
Financial resource → Overall satisfaction 0.1090 0.0165 <.0001 
Financial resource → Limited access to care -0.1250 0.0166 <.0001 
Age → Limited access to care 0.0034 0.0167 0.8390 
 
Figure 6. Path diagram of the final structural equation modeling  
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Table 9. Standardized total, direct, and indirect effects 
Predictor Through 
Causal effect 
Total Direct Indirect 
Medication 
unaffordability 
-  0.5500 - 
Overall satisfaction  - 0.0062 
Total 0.5562 0.5500 0.0062 
Financial resource -  -0.0720 - 
Medication unaffordability  - -0.0665 
Overall satisfaction  - -0.0069 
Medication unaffordability → 
Overall Satisfaction 
 - -0.0008 
Limited access to healthcare → 
Medication unaffordability 
 - -0.0087 
Limited access to healthcare → 
Medication unaffordability → 
Overall satisfaction 
 - -0.0001 
Limited access to healthcare → 
Overall satisfaction 
 - -0.0011 
Total -0.1561 -0.0720 -0.0841 
Having serious mental 
illness (SMI) 
-  0.0442 - 
Medication unaffordability  - 0.0578 
Medication unaffordability  → 
Overall satisfaction 
 - 
0.0007 
Total 0.1027 0.0442 0.0585 
Limited access to 
healthcare 
Overall satisfaction  - 0.0090 
Medication unaffordability  - 0.0693 
Medication unaffordability  → 
Overall satisfaction 
 - 0.0008 
Total 0.0791 - 0.0791 
Overall satisfaction -  -0.0633 - 
Total -0.0633 -0.0633 - 
Age (75 years or older) Medication unaffordability  - -0.0376 
Medication unaffordability → 
Overall Satisfaction 
 - 
-0.0004 
Total -0.0380 - -0.0380 
 
4.4.4.Total, Direct, and Indirect Effects 
Table 9 presents the total, direct, and indirect effects of the model. Medication 
unaffordability had the strongest total effects on CRN, followed by financial resources, 
presence of SMI, limited access to healthcare, and overall satisfaction. Age had the least 
total effects on CRN. Approximately half of the effects of financial resources on CRN 
 84 
 
 
were mediated through medication unaffordability, limited access to healthcare, and 
overall satisfaction (direct effects = -0.0720; indirect effects = -0.0841). 
 
4.5. Discussion 
In this study, the causal paths between financial resources, patient’s attitudes, and 
CRN were explored based on the extended Proximal-Distal Continuum of Adherence 
Drivers Model. As hypothesized under the conceptual framework, perceived 
affordability was the strongest predictor of CRN, and this finding is consistent with the 
prior research [19]. From a national sample of adults with one or more chronic 
conditions, McHorney and Spain [26] found that medication affordability is the most 
common reason for medication non-adherence (about 50%). In agreement with the 
current study finding, McHorney et al. [19] found that the odds of engaging in 
medication non-adherence among those with the least perceived affordability was 
significantly-greater than the odds among those with the highest perceived affordability. 
The difference between their study and the current study is that their study looked at 
overall medication non-adherence among the general population, while the current study 
focused only on cost-related medication non-adherence among older adults. The current 
study reaffirms the previous finding and strengthens the evidence. 
The current study demonstrated that the effects of poverty on CRN were 
mediated through patient’s attitudes, such as perceived medication affordability, 
perceived access to care, and patient satisfaction. Extant studies suggest that the 
relationship between financial pressure and medication non-adherence is complex, and 
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financial pressure cannot solely explain the behavior. For example, in the Piette’s study 
[20], there was a substantial variation in CRN for preventive versus symptom-relief 
medication types among middle-aged and older adults with chronic diseases.  Piette et 
al. [20] found that patients were significantly more likely to report CRN on symptom-
relief medication than on preventive medications. Such an observation is potentially 
attributed to the differences in patients’ attitudes towards different medication types. 
In a separate study, Piette et al. [27] showed that CRN was observed in both low- 
and high-income populations, and that having low perceived need for medication and 
perceived medication concerns (e.g., side effects) were positively associated with CRN 
in both low- and high-income populations. In their study, Piette et al. [27] examined not 
only the effects of patients’ attitudes, but also the effects of depression. Similar to our 
study, they found the significant association between depression and CRN. The 
difference between their and our study is that while their study focused on independent 
effects of patients’ attitudes and depression on CRN by the degree of financial pressure, 
the current study focused on the causal paths that link these multiple factors together. 
In this study, satisfaction with overall healthcare services was adversely 
associated with CRN. This is consistent with the previous findings. Oetzel et al. [28] 
indicated a weak, positive correlation between patient satisfaction and medication 
adherence among patients with HIV/AIDS (r = 0178, p < 0.05). However, their studies 
did not examine the independent effects of patient satisfaction on medication non-
adherence, and the study population was different from the current study. In the current 
study, access to healthcare (non-financial) had weak indirect effects on CRN via 
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medication affordability and patient satisfaction but did not have any direct effects on 
CRN. This potentially explains the conflicting findings in the literature about the 
relationship between access to healthcare (non-financial) and CRN. 
As hypothesized under the Proximal-Distal Continuum of Adherence Drivers 
Model, age had a relatively weaker effect on CRN compared to other variables examined 
in the model. The observation is not surprising considering that the past literature has 
shown conflicting findings about the relationship between age and medication non-
adherence. For example, two studies about medication adherence to adjuvant hormonal 
therapy in breast cancer patients showed conflicting findings about age: one study 
indicated older age (i.e., > 70 years old) as a potential barrier to medication adherence 
[29]; but another study indicated younger age (i.e., < 70 years old) as a potential barrier 
to medication adherence [30]. A systematic review indicated that extremes of age (i.e., 
younger than 45-50 years old or older than 65-75 years old) was largely and negatively 
associated with medication adherence [31]. However, the findings of the review focused 
specifically on female breast cancer survivors who were on adjuvant hormonal therapy, 
hence their findings may not be generalizable to a different population. 
This study has some limitations. First, the cross-sectional nature of the data limits 
examination of the hypothesized causality, and the SEM approach permeates testing of 
the causality that was hypothesized based on the past literature. Second, the study relied 
on the self-reported data, and, hence, the reported information cannot be verified. 
However, self-reported data on medication non-adherence can be rich with contextual 
information and enable researchers to identify types of medication non-adherence (e.g., 
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intentional versus unintentional and cost-related versus not cost-related). Third, this 
survey had only a single item on satisfaction with healthcare, and the variable response 
was highly skewed. While the patient satisfaction measure was complemented by using 
separate measures of perceived access to care, the study still lacks the data on other 
dimensions of patient satisfaction. Fourth, the tested model did not include some 
potentially-important drivers, such as perceived need and concerns for medication. The 
model explained only about one-third of the variance of CRN, and inclusion of other 
important determinants may further improve the model’s explanatory power. Lastly, the 
listwise deletion approach was used for handling the missing data, and more than 25% of 
the cases were omitted under this approach. Those who did not report any problems with 
access to healthcare services were more likely to be omitted from the analysis, and, 
therefore, the likelihood of having access to healthcare services would have been biased 
downward under the approach. Also, using the listwise deletion approach tends to result 
in larger standard errors and wider confidence intervals due to lower power. To 
overcome this limitation, the structural equation model was performed with alternative 
financial resource-related variables (e.g., concerned about running out of food) that had 
low missing rate, and there was no meaningful change to the results (i.e., no changes in 
statistical significance and minimal changes in regression coefficients).  
Despite these limitations, this study has some strengths. First, this is one of the 
few studies that attempted to explore the causal paths between financial resource and 
CRN and to understand the potential effects of patient attitudes on the relationship. 
Second, this study used a nationally-representative dataset.  
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4.6. Summary and Future Implication 
The current study attempted to provide an explanation for the relationship 
between financial pressure, patients’ attitudes (e.g., perceived medication affordability, 
access to care, and patient satisfaction), and CRN that have not been examined 
previously. The study findings suggest that perceived medication affordability is the key 
driver of CRN, and effects of poverty on CRN is mediated through patients’ perceived 
medication affordability, perceived access to care, and satisfaction with healthcare. 
While multiple possible pharmaceutical policy reforms (e.g., government’s active 
involvement in determining prescription-drug price) should be discussed for addressing 
the financial-related factors that drive medication non-adherence [32], there are many 
uncertainties at this stage of health policy turmoil. Meanwhile, this study finding implies 
that CRN in older adults can not only be reduced by reducing their financial pressure but 
also by modifying their attitudes. In addition to the need for senior-friendly public health 
interventions that address these modifiable barriers in older adults with chronic 
conditions, the study limitations also suggest future studies that can test more 
comprehensive models. More comprehensive models should include not only the 
patient-related factors but also provider-, prescription-, and system-related factors. 
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5. SUMMARY AND CONCLUSIONS 
 
 
Use of pharmacotherapy or medication treatment has become more prevalent in 
the US over the past decades. Poor medication adherence is a persistent public health 
challenge associated with treatment ineffectiveness and adverse health outcomes, 
increased healthcare costs, and even death. This dissertation was proposed and 
completed under the hypothesis that medication non-adherence is influenced by multiple 
modifiable factors and can be improved.  
The interaction between patients and their healthcare providers is one of the most 
important social activities that can influence the patients’ chronic disease self-
management behavior, including medication adherence. However, the patient-provider 
interaction can be described in many ways, such as affective or instrumental interaction. 
Understanding how different aspects of a patient-provider interaction are related to 
medication adherence will enable the formulation of effective medical interaction 
strategies for reducing medication non-adherence. Hence, the first study of this 
dissertation was a systematic literature review aimed at summarizing the prevalence of 
medication non-adherence among community-dwelling older adults, as well as providing 
an overview of the association between the different aspects of patient-provider 
relationship and medication adherence among community-dwelling older adults. 
Through the comprehensive literature search, ten articles with a total sample size of 
25,010 patients were included in this systematic literature review. The reported 
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medication non-adherence rate ranged from 14% to 52%, with the mean medication non-
adherence rate of 33%. This is similar to the previously-reported medication non-
adherence rates in other reviews. The reported medication non-adherence rate was 
higher in the non-US countries (45%) than in US (33%). Most of the studies focused on 
the instrumental interaction type, such as information exchange. While information 
exchange was positively associated with the patients’ medication adherence, discussion 
about barriers or making adherence easier was negatively associated with patients’ 
medication adherence. It would be important to understand the context and dynamic 
nature of the medical interaction beyond the snapshot to properly interpret the observed 
relationship. There is a need for studies that utilize longitudinal research design or 
complex dynamic systems science perspective. Furthermore, the evidence was weak and 
suggests opportunities for more vigorous researches. For example, using multiple 
standardized medication adherence measurements of medication adherence can produce 
stronger evidence that can be summarized and compared. 
The second study of this dissertation aimed at exploring and evaluating the long-
term effects of an evidence-based cognitive and behavioral intervention on medication 
adherence among older adults. Given that prior research indicated that complex 
interventions with multiple components had a greater likelihood of success in improving 
medication adherence, we chose the Chronic Disease Self-Management Program 
(CDSMP) for the study.  Not only has CDSMP been widely disseminated and 
implemented in multiple community settings, it has also been shown to be successful in 
improving medication adherence among its participants in long-term. This second study 
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went beyond prior investigation of the long-term effects of CDSMP on medication 
adherence among the older participants to examine the potential effects of other 
determinants of medication adherence, such as self-rated health, depression, and 
communication with doctors, on the program impacts. It was hypothesized that the short-
term effects of CDSMP on self-rated health, depression, and communication with 
doctors could influence medication adherence in long-term.  
Using the national CDSMP evaluation data, this second study showed that 
CDSMP had a statistically-significant long-term effect on medication adherence among 
the older participants but not short-term effects, confirming the prior findings. There are 
three key observations from this study to be highlighted. First, this study showed that the 
improvements in medication adherence were largely contributed by the improvements in 
unintentional medication non-adherence, rather than intentional medication non-
adherence. This implies the importance of understanding the differences between 
intentional and unintentional medication non-adherence and the needs for different 
approaches to address the different types of medication non-adherence. Second, the older 
participants who had depressive symptoms at the baseline showed the greater 
improvements in medication adherence than those without depressive symptoms at the 
baseline. Along with the first key observation, this finding has important implications for 
the program recruitment, as well as for future research. Interventions, such as CDSMP, 
can be more beneficial to a population with a greater likelihood of unintentional 
medication non-adherence or a population with depressive symptoms. Third, the 
hypothesis that the short-term effects of CDSMP on self-rated health, depression, and 
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communication with doctors could influence medication adherence in long-term was 
partially supported. The changes in self-rated health and depression during the first six 
months from the baseline assessment moderated the changes in medication adherence 
during the last six months from the six-month follow-up assessment. Improving 
depression during the first six months was associated with a greater improvement in 
unintentional medication non-adherence during the last six months. On the other hand, 
improving self-rated health during the first six months was associated with a greater 
engagement in intentional medication non-adherence during the last six months.  
Understanding for the underlying mechanism of the program impacts on medication 
adherence will enable better targeting, as well as supplementing the program for better 
outcomes. For example, highlighting the importance of medication adherence regardless 
of improved health status may prevent the older participants from engaging in 
intentional medication non-adherence after their health improved. Furthermore, this 
finding, again, highlights the potential need for different approaches to address 
intentional and unintentional medication non-adherence.  
The third study of this dissertation focused on cost-related medication non-
adherence (CRN). While financial factors are thought to be the main drivers of CRN, 
CRN is also influenced by the patient’s characteristics, such as sociodemographic 
characteristics and attitudes, and the patient’s health condition. In this study, the 
potential causal paths involving poverty, patient attitudes, and CRN were hypothesized 
based on the modified Proximal-Distal Continuum of Adherence Drivers Model, and 
tested using the structural equation model using the 2015 National Health Interview 
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Survey. The final model had a good-to-fair fit. Poorer perceived-medication 
affordability, lower patient satisfaction, less financial resources, and the presence of 
serious mental illness predicted a greater likelihood of CRN. Medication affordability 
was the strongest predictor of CRN, followed by financial resources, the presence of 
serious mental illness, access to healthcare, and patient satisfaction. Furthermore, about 
half of the effects of financial resources on CRN was mediated through patients’ 
attitudes. This study can inform future interventions for improving CRN by the 
application of behavioral strategies to modify older adults’ perceptions and attitudes. 
Future research can also be deigned to overcome some of the current study’s limitation 
(e.g., inclusion of other proximal factors that are known to be strongly associated with 
CRN). 
In summary, this dissertation reaffirmed that changes in medication adherence is 
associated with multiple factors that may also be associated with one another. What this 
also suggests is the need for future studies that can examine the complex nature of this 
mechanism that is likely to be beyond a linear relationship between just one factor and 
medication adherence. Understanding and acting upon this complexity can contribute to 
intervention implementation and dissemination.  
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APPENDIX A 
SUMMARY OF THE TEN STUDIES INCLUDED IN SECTION 2  
(SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS) 
 
Table A1. Summary of the studies included in the current systematic literature review  
Table A1. (Continued) 
Studies 
Medication 
adherence 
measurements  
Patient-provider 
relationship (PPR) 
measurements  Control variables 
Prevalence of 
medication 
adherence  
Estimated 
association between 
medication 
adherence and 
measurements 
(Study reference, 
country, total sample 
size (n), chronic 
diseases, types of 
provider) 
(Data collection 
method (reported by 
whom); definition of 
measures; measure 
range (interpretation 
of the measure)) 
(Data collection 
method (reported by 
whom); definition of 
measure; measure 
range (interpretation 
of the measure)) 
  (Performed analyses, 
reported metrics, 
reported metric 
values, direction of 
effect) 
Heisler et al, 2007 
- US 
- n = 1558 
- Diabetes 
- Physicians 
-Self-reported 
(patients); 
-Difficulty in 
following diabetes 
medication as 
prescribed in the past 
6 months; 
-ranged from 0-100 
(higher = better) 
- Self-reported 
(patients); 
- Provider’s 
information provision 
from the ABIM and 
patient’s involvement 
in decision-making 
from the PACIC scale 
- Each measure ranged 
from 0-100 (higher = 
better) 
Age, sex, ethnicity, 
education, income, 
medical regimen, 
diabetes comorbidity, 
diabetes duration, and 
duration of PPR. 
Not reported - Multivariate linear 
regression 
- Standardized 
regression coefficients 
(βstandardized ) 
- βstandardized = 0.13* 
(Positive; medication 
adherence and 
provider’s information 
provision) 
- βstandardized = 0.03 (No 
difference; medication 
adherence and 
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Table A1. (Continued) 
Studies 
Medication 
adherence 
measurements  
Patient-provider 
relationship (PPR) 
measurements  Control variables 
Prevalence of 
medication 
adherence  
Estimated 
association between 
medication 
adherence and 
measurements 
patient’s involvement 
in decision-making) 
Kressin et al., 2007 
- US 
- n = 793 
- BP (blood pressure) 
- Doctors 
- Self-reported 
(patients); 
- Forgetting to take 
medication, not taking 
medications on 
purpose, taking less 
medications because 
of perceptions that one 
needed less, and 
having difficulties 
taking medication as 
prescribed 
- Binary (Non-
adherent (=0) if 
reported any problem 
to at least 1 of the 
medication adherence 
items) 
- Self-reported 
(patients); 
- Having patient-
doctor discussion 
about making it easier 
to take your BP meds 
- Binary (1 = Yes) 
Race, self-efficacy in 
taking BP as 
prescribed, told to 
split any BP pills by 
providers, perceived 
BP status, and site of 
care 
77%  - Multivariate logistic 
regression 
- Odd ratio (OR) 
- OR = 0.56* 
(Negative) 
Wilson et al., 2007 
- US 
- n = 17569 
- Did not focus on a 
specific health 
condition 
- Physicians  
- Self-reported 
(patients); 
- CRN, non-adherence 
because of medication 
experiences (e.g., side 
effects), non-
adherence because of 
self-assessed need for 
medication in the past 
12 months 
- Self-reported 
(patients); 
- Any patient-
physician dialogue in 
the past 12 months 
about medication costs 
and changing a 
medicine because of 
patients’ medication 
experience 
None 60% - Performed analysis 
was unclear 
- Proportions 
(e.g., among those 
who had patient-
physician dialogue 
about changing 
prescription due to 
patients’ medication 
experience (40%), 
52% reported the 
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Table A1. (Continued) 
Studies 
Medication 
adherence 
measurements  
Patient-provider 
relationship (PPR) 
measurements  Control variables 
Prevalence of 
medication 
adherence  
Estimated 
association between 
medication 
adherence and 
measurements 
- Binary (Non-
adherent if reported 
any problem to at least 
1 of the medication 
adherence items) 
- Each measure was 
binary (1=Yes)  
medication non-
adherent.) 
- Negativea* (for both 
types of patient-
physician dialogues) 
Donohue et al., 2009 
- US 
- n = 1001 
- Did not focus on a 
specific health 
condition 
- Doctors 
- Self-reported 
(patients); 
- CRN in the past 12 
months 
- Binary (CRN (=1) if 
reported any CRN 
problem) 
- Self-reported 
(patients); 
- Trust doctor to 
provide price-related 
information  
- Dichotomized (1 = 
trust) 
Age, sex, 
race/ethnicity, 
education, marital 
status, income, 
number of drugs, drug 
spending, and drug 
insurance coverage  
- Not reported - Multivariate logistic 
regression 
- OR 
- OR = 0.71 (No 
difference; among 
those who reported 
not having a problem 
with drug costs) 
- OR = 0.77 (No 
difference; among 
those who reported 
having a problem with 
drug costs) 
Turner et al., 2009 
- US 
- n = 202 
- BP 
- Doctors or nurses 
- Self-reported 
(patients); 
- Last time missing 
any BP medication 
- Dichotomized (Non-
adherent if missed any 
dose within the past 3 
months) 
- Self-reported 
(patients); 
- Patient’s perception 
of how often his/her 
doctor/nurse listened 
careful to the patient 
- Dichotomized (1 = 
Yes)  
age, race/ethnicity, 
number of bp meds, 
general health, mood 
disorder, check bp at 
home, not aware of 
medicare part d, had 
to go without usual bp 
med because not 
covered, running out 
of pills sometimes, 
trouble following 
doc's advice about 
taking meds, feel 
78% - Multivariate logistic 
regression 
- OR = 1.04 (No 
difference) 
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Table A1. (Continued) 
Studies 
Medication 
adherence 
measurements  
Patient-provider 
relationship (PPR) 
measurements  Control variables 
Prevalence of 
medication 
adherence  
Estimated 
association between 
medication 
adherence and 
measurements 
unimportant to fill 
prescription quickly, 
important to talk 
about bp with 
doc/nurse, bp 
knowledge 
Luz et al., 2011 
- Brazil 
- n = 1017 
- Did not focus on a 
specific health 
condition 
- Physicians 
- Self-reported 
(patients); 
- CRN in the past 30 
days 
- Binary (CRN (=1) if 
reported any CRN 
problem) 
- Self-reported 
(patients); 
- Frequency of patient-
physician dialogue 
about health/treatment 
- Dichotomized (1 = 
rarely/never having 
patient-physician 
dialogue about 
health/treatment)  
None Not Reported - Pearson’s chi-square 
test 
- Prevalence ratio 
(PR) 
- PR = 2.72 (No 
difference) 
Guz et al., 2013 
- Philippine 
- n = 325 
- Did not focus on a 
specific health 
condition 
- Doctors 
- Self-reported 
(patients);  
- Morisky Mdication 
Adherence Scale 
(MMAS-8) 
- Trichotomized into 
high, medium, and 
low adherence 
- Self-reported 
(patients); 
- Patients’ trust in their 
physicians 
- Binary (1 = Trust) 
(Not control variables, 
but other predicting 
variables in the SEM: 
patients’ consultation 
satisfaction, 
depression, memory 
load, number of 
medical conditions, 
external memory 
strategy, event-based 
memory task) 
59%b - Structural equation 
modelling 
- Regression 
coefficientsc (β) = 
1.168* (Positive) 
Halt et al., 2013 
- US 
- n = 2194 
- BP 
- Self-reported 
(patients); 
- MMAS-8 
- Self-reported 
(patients); 
Age, race, marital 
status, education, 
comorbidity, reduced 
BP medications 
86% -Multivariate logistic 
regression 
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Table A1. (Continued) 
Studies 
Medication 
adherence 
measurements  
Patient-provider 
relationship (PPR) 
measurements  Control variables 
Prevalence of 
medication 
adherence  
Estimated 
association between 
medication 
adherence and 
measurements 
- Did not focus on a 
specific provider type 
- Dichotomized (1 = 
Non-adherent) 
- Patients’ satisfaction 
with communication 
with providers 
- Binary (1 = Not 
satisfied) 
because of cost, 
lifestyle 
modifications, 
depression, sexual 
functioning, BMI 
- OR = 1.16 (No 
difference; among 
men) 
- OR = 1.75 (Positive; 
among women) 
Jin et al., 2016 
- Republic of Korea 
- n = 160 
- Did not focus on a 
specific health 
condition 
- Pharmacists 
- Self-reported 
(patients); 
- Adherence to Refills 
and Medication Scale 
(ARMS) 
- Ranged 12-48 (lower 
= better adherence) 
(Non-adherent if the 
score is 20 or higher) 
- Self-reported 
(patients); 
- Patient-pharmacist 
relationship and 
communication 
(dissatisfaction/ 
neutral/ satisfaction) 
- Pharmacists’ 
explanations of 
medication (none/ a 
little/ none) 
age, education level, 
health-related 
problems, health 
literacy, frequency of 
doses, satisfaction 
with pharmacist’s 
counseling, and 
(patient-pharmacist 
relationship and 
communication or 
explanation of 
medication) 
 
48% - Multivariate linear 
regression 
- Unstandardized 
regression coefficients 
(βunstandardized ) 
- βunstandardized = 0.022 
(No difference; 
patient-pharmacist 
relationship and 
communication) 
- βunstandardized = -2.945 
(Positive; explanation 
of medication) 
Lee et al., 2017 
- US 
- n = 191 
- BP 
- Physicians 
- Self-reported 
(patients); 
- MMAS-8 
- Ranges from 0-8 
(higher = better 
adherence) 
- Self-reported 
(patients);  
- Quality of 
information exchanged 
from PCAS 
- ranges from 25-100 
(higher = better 
informative 
communication) 
Age, sex, education, 
race, income, live 
alone marital status, 
comorbidity class 
 
Not reported - Multivariate linear 
regression 
- βstandardized = 0.25* 
(Positive)  
 
